Mild Hyperthermia and Thermosensitive Liposomes for Chemotherapy by Li, L. (Li)

The author appreciates the generosity of 
 
Erasmus MC
Department of Surgery
The research for this thesis was performed within the framework of the 
Erasmus Postgraduate School Molecular Medicine.
Mild Hyperthermia and Thermosensitive Liposomes 
for Chemotherapy
Li Li
ISBN: 978-94-6182-235-2 
Printed by Off Page, Amsterdam 
Layout & Cover design by Li Li 
© Li Li, Rotterdam, 2013 
All rights reserved. No part of this thesis may be reproduced or transmitted in 
any form by any means, without permission of the author or corresponding 
journal. 
Mild Hyperthermia and Thermosensitive Liposomes 
for Chemotherapy
Milde hyperthermie en thermosensitieve liposomen 
voor chemotherapie
THESIS 
to obtain the degree of Doctor from Erasmus University Rotterdam
by command of the rector magnificus
Prof.dr. H.G. Schmidt 
and according to the decision of the Doctorate Board 
The public defense is held on Thursday, March 28, 2013
at 3.30 pm 
by
Li Li
born in Fushun, Liaoning, P.R. China
Doctoral committee
Promotor  Prof.dr. A.M.M. Eggermont 
Other members Prof.dr. R.J. Griffin 
   Prof.dr. G. Storm 
   Prof.dr. G.C. van Rhoon 
Co-promotor  Dr. G.A. Koning 
In memory of my grandparents. 
怀念姥爷，姥姥。 

“If a man can... make a better mousetrap, the world will make a beaten 
path to his door.”
Ralph Waldo Emerson
Forward
Mark Dewhirst, D.V.M., Ph.D.
This thesis contains 7 chapters that summarize an immense body of work 
centered on the demonstration of utility of a long circulating low temperature 
sensitive doxorubicin containing liposome (Dox-TSL). The work in total 
clearly demonstrates the utility of this approach and suggests that it may have 
superior qualities to thermally sensitive liposome that has a shorter circulation 
time [1]. Altogether, the ability to harness triggered drug release holds great 
promise for a number of clinical applications, where enhanced drug delivery 
may make the difference between treatment success and treatment failure. The 
advantage of being able to control the spatial distribution of drug delivery has 
important implications for increasing efficacy as well as decreasing normal 
tissue toxicity. 
The enhanced permeability and retention (EPR) effect has provided rationale 
for nanoparticle delivery, since the first description of this phenomenon by 
Maeda [2-3]. However, the promise of the EPR effect to improve nanoparticle 
drug delivery has met with modest success in the clinic. The flagship liposomal 
drug, Doxil™, was approved for use on the basis of less cardiotoxicity 
compared with free drug, as opposed to improved anti-tumor effect [4].  
In parallel with the development of Doxil™, there was the increasing 
appreciation for the fact that hyperthermia augmented liposomal drug 
delivery to tumors. This effect was first reported by Yatvin [5], and verified 
by a number of additional authors, as summarized in a comprehensive 
review by Kong and Dewhirst[6]. Although there appeared to be consistent, 
but variable improvement of liposomal drug delivery by hyperthermia, the 
underlying mechanism for this effect was not understood. Adding to the 
confusion in the field was the development of thermally sensitive liposomes. 
For these formulations, it was not possible to ascertain whether augmented 
drug delivery was a consequence of heat mediated-liposomal drug release or 
enhanced liposome extravasation, or both. It is clear that the answer to these 
questions is complex – likely influenced by liposome formulation and size, 
temperature of heating and tumor type. 
Gaber et al. were the first to study liposome extravasation vs. content release, 
using the original thermosensitive liposome formulation of Yatvin (DPPC, 
HSPC, CHOL, PEGPE, at a molar ratio of 100:50:30:6) with the addition of 
polyethylene glycol  (PEGPE) to extend the circulation time [7].  In this work, 
they used the skin-fold window chamber model in Fischer 344 rats to evaluate 
these two features of drug delivery, using doxorubicin to monitor content 
release and a fluorescently labeled lipid to monitor delivery of liposomes. The 
R3230Ac mammary carcinoma was used as the tumor model.  This formulation 
exhibits rather slow kinetics of drug release, hence accumulation of drug in 
this tumor model was a product of both enhanced drug delivery and drug 
release at both 42 and 45°C.
Kong et al. were the first to systematically evaluate the effects of hyperthermia 
on liposomal drug delivery and release, using the SKOV3 ovarian 
carcinoma model, grown in the skin fold window chamber. This tumor was 
chosen because it was impermeable to 100nm liposomes when studied in 
normothermic conditions (34°C). In contrast to the elegant work of Dr. Li in 
this thesis, these mice were housed in environmental chambers at an ambient 
temperature of 34°C, so the lack of vascular permeability at 34°C represents 
the control condition. Important features of this work included the following 
observations: 1) The rate of liposomal extravasation was linearly dependent 
upon temperature in the range between 40 and 42°C, 2) The enhancement 
in permeability persisted out to 6 hours post treatment and reestablishment 
of permeability was not attainable if reheating was used 8hr after an initial 
heating [8]. The results of this work suggested that rearrangements of the 
cytoskeleton were responsible for increased endothelial cell gap size with 
heating. The supposition that the cytoskeleton was involved relates to 
the fact that denaturation of protein is a major target of cell damage from 
hyperthermia [9]. Arrhenius analysis of the rate of heat inactivation for 
proteins vs. temperature shows that the rate doubles for every degree rise in 
temperature. In the work of Kong, the liposomal extravasation rate doubled 
for each degree of temperature rise consistent with the supposition that 
protein denaturation was responsible for the increase in pore size. Further 
evidence for this hypothesis came from the acquired resistance to reopening 
of pores with a second heat treatment. This latter observation suggested that 
the increase in pore size was likely due to opening of endothelial cell gaps, 
which are maintained by cellular cytoskeleton. The resistance to reopening 
was likely the result of thermotolerance, which would create resistance  to 
cytoskeletal rearrangements [10], 3) 42°C heating increased vascular pore sizes 
to as large as 400nm, since thermal augmentation of liposomal extravasation 
occurred up to that size [11].  
Although the work of Kong was thorough with respect to studying various 
parameters that might influence thermally mediated liposomal extravasation, 
there were several limitations to the work. First, all of the studies were 
done in one tumor line. Information on variability of these thermal effects 
will broaden our knowledge base about the general applicability of this 
approach. Second, the studies were performed with less than ideal optics 
and were done at relatively high power using epifluorescence. Because of 
this, it was not possible to assess intratumoral heterogeneity, nor assess the 
magnitude enhanced extravasation at depth. Dr. Li’s third chapter presents 
a comprehensive step forward in our understanding of how to exploit the 
use of hyperthermia to augment drug delivery to tumors. The utilization of 
transgenic mice that express green fluorescence protein in endothelial cells, 
combined with high resolution confocal microscopy to visualize drug delivery 
has revealed important information about the uniformity of the effects of heat 
on liposomal extravasation and the extent of variation between tumor types. 
Her results also reveal that the enhanced extravasation after heating may be 
prolonged in some tumors, beyond the 6 hour window originally reported by 
Kong [8]. In fact, it is likely that such effects occur in spontaneous tumors as 
well. Matteuci examined radiolabelled liposome accumulation in companion 
cats with vaccine associated fibrosarcomas [12]. Here, enhanced extravasation 
was observed for up to 16 hours after application of local hyperthermia in 
several individuals.  
The variability in the enhancement of liposome extravasation between and 
within tumors raises the rationale for using imaging to monitor drug delivery. 
With respect to delivery of liposomes, one of the most promising methods is 
to use technicium-99-m radiolabelled liposomes. The method to radiolabel 
liposomes with this tracer is quite straightforward and subsequent imaging 
can be accomplished with SPECT imaging, to yield volume distributions. 
Kleiter et al, reported that co-administration of radiolabelled liposomes along 
with Doxil can accurately reflect the doxorubicin concentration in tissues at 18 
hour after administration of hyperthermia [13].
In her fourth chapter, Dr. Li presents provocative data related to a sterically 
stabilized thermosensitive liposome. In this chapter, she compares the in 
vitro drug release characteristics of the sterically stabilized thermosensitive 
liposome (Dox-TSL) to the Dox-LTSL of Needham. She also examined the 
delivery of doxorubicin to tumors, using high resolution intravital microscopy. 
As has been reported by Manzoor using Dox-LTSL, hyperthermia causes 
intravascular drug release and increased drug penetration into tumor, with 
specific accumulation in tumor and endothelial cell nuclei [14]. Growth delay 
data, comparing the Dox-TSL to Dox-LTSL revealed improved anti-tumor 
effect for both compared with controls. Dox-TSL revealed a trend toward 
being more effective than Dox-LTSL; a statistical comparison was not reported, 
however.
In the fifth chapter, Dr. Li explores the relative efficacy of a two-step drug 
delivery approach that combines the thermally enhanced EPR effect with 
heat mediated drug release. Two different Dox-TSL formulations were 
compared: fast release (Dox-fTSL, rapid drug release within 5 min) and 
slow release (Dox-sTSL) release over an hour of heating. To do the two step 
approach, the tumor is heated twice; the first time this is done to increase 
EPR and liposomes are not administered until after first heat is concluded. 
The second heat is delivered several hours later, to rapidly release the drug 
from extravasated liposomes. The long circulation time of the Dox-TSL makes 
this approach feasible.  Although the two step approach seems attractive in 
theory, the anti-tumor effect of Dox-TSL  administered during hyperthermia 
yielded better antitumor effect. It would be interesting nonetheless to consider 
giving a second heat a day or two later, even with the Dox-fTSL, because one 
presumes that liposomes with unreleased drug would continue to accumulate 
in the tumor even after heat is concluded. By waiting a day or two after 
hyperthermia treatment is concluded, any effects of thermotolerance, which 
will decrease efficacy of doxorubicin [15], would have decayed. Dr. Li looked 
at this possibility, but only at 4 hour after heating. Peak thermotolerance levels 
occur during heating at 41°C for 60 min, decay by 50% by 4 hour, and return 
to baseline levels within 24h in theHA-1 cell line [16]. Thus, there is merit in 
considering a second heat treatment a day later, if the temperatures within 
the tumor can be maintained around 41°C. Dr. Li recommends the two step 
approach to “limit normal tissue toxicity” from rapid drug release in normal 
tissues during heating. Theoretically, this might be an issue, but in phase I 
trials in dogs [17] and humans [18] in which the Dox-LTSL formulation has 
been tested, there has not been evidence for normal tissue toxicity that could 
be attributable to doxorubicin.  
By comparison, a two step approach cannot be used with Dox-LTSL. As is 
pointed out by Dr. Li, the original thermosensitive formulation developed by 
Needham exhibits some drug release at normothermia;  it has a circulation half-
life of about 60 min in humans [19, 18]. Thus, this liposome is not amenable to 
taking advantage of the heat-enhanced EPR effect. In fact, the short half-life of 
this drug can challenge its clinical application. To take maximal advantage of 
Dox-LTSL, it is ideal to initiate heating first and then give drug when the tumor 
has already reached thermal steady state. This requirement is challenging 
in the clinic, where the chemotherapy suite may often be physically located 
separately from the hyperthermia facilities. Additionally, the short circulation 
time restricts the application to heating of one region. If one desired to treat 
more than one lesion in the same patient, it would be quite challenging, 
because by the time the first heat is completed, circulating drug levels will 
have diminished to subtherapeutic levels. The advantages of the Dox-TSL are 
obvious, when compared with Dox-LTSL, even without considering the two 
step approach.  
The sixth chapter deals with the concept of pulsed heating, which might be 
encountered if one elected to use this Dox-TSL in combination with high 
intensity focused ultrasound. Here, Dr. Li shows that pulsed heating (5cycles 
of 5 min at 42C with 10 min at normothermia) yields drug levels nearly 
equivalent to continuous low temperature heating and similar anti-tumor 
effects in a human melanoma xenograft. This observation will be of interest to 
the growing number of investigators interested in combining thermosensitive 
liposomes with HIFU [20-24].
In summary, this body of work sets the stage for the next steps in development 
of Dox-TSL. I look forward to seeing it develop into a legitimate therapeutic 
approach for a variety of human cancers.
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Introduction
Chemotherapy in cancer 
Conventional chemotherapy relies on cytotoxic compounds to suppress 
cancer development. These compounds non-selectively attack proliferating 
cells in tumors, but also at other sites in the body, leading to toxicity in healthy 
organs and tissues. The systemic toxicity is related to the aspecificity of the 
cytotoxic compounds, their large volume of distribution, short circulation 
half-lives that all require high dosing to obtain therapeutic levels at tumors. 
For example, doxorubicin (Dox) is an anthracycline antibiotic, which is 
widely used in cancer treatments [1]. Although Dox can effectively kill cancer 
cells by intercalating with DNA to inhibit cell proliferation, it is limited in 
clinical use because of its severe cardiotoxicity and myelosuppression, which 
are the dose limiting toxicities. Dox cardiotoxicity may manifest acute in the 
form of tachycardia or arrythmias and as delayed cardiomyopathy including 
congestive heart failure, during or after the course of treatment. In addition, 
Dox may cause nausea and vomiting and can affect other tissues such as 
bone marrow, causing e.g. myelosuppression and may due to its carcinogenic 
nature also induce secondary hematological cancers.  
Liposomal chemotherapy 
Liposomes are potent biocompatible nanocarriers, widely used to deliver 
cytotoxic compounds, genetic materials, and contrast agents for therapies 
and imaging. A draw-back of the initially proposed liposomal carriers was the 
relatively fast clearance. In order to prevent liposomes from being recognized 
and taken up by the reticuloendothelial system (RES), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-polyethylene glycol2000 (DSPE-PEG2000) 
is commonly grafted on the lipid membrane to prolong liposome retention 
in circulation [2]. A well known and most widely used chemotherapeutic 
liposomal Dox formulation is Caelyx® (in Europe) also known as Doxil® (in 
USA), which is a pegylated liposomal Dox (PLD). The formulation reduces the 
systemic side-effects of Dox by encapsulating the drug into long circulating 
liposomes, which strongly prolongs the circulation half-life of Dox [3-5]. 
Moreover, PLD can also extravasate through leaky tumor vasculature to locally 
accumulate in tumors [6]. However, PLD causes a new dose limiting side-effect, 
i.e. hand-foot syndrome related to the passive targeting of the nanocarriers to 
the skin especially at hands and feet, where Dox is slowly released causing 
toxicity. PLD improves treatment outcome in Kaposi sarcoma, and head and 
neck tumors [7-8]. However, PLD shows limited efficacy in sarcoma and 
breast cancer [3, 5]. The essential drawback of PLD is the slow Dox release 
and lack of tumor specific targeting, which impedes its therapeutic efficacy 
[9-11]. Studies on improving liposomal chemotherapy involve manipulation 
of tumor microenvironment and design of novel nanovesicles with improved 
drug delivery potential. 
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Liposomal drug delivery mechanism involves extravasation through permeable 
tumor vasculature and deposition of liposomal drugs into the interstitial space 
in tumors [12-14]. Upon liposome extravasation through the permeable tumor 
vasculature, liposomes may penetrate further in the interstitial space. However, 
due to liposome size and the compact nature of the interstitial matrix in tumors, 
liposome penetration depth in the extravascular extracellular space (EES) is 
limited [15-16]. It is noteworthy to emphasize that the heterogeneity of tumor 
vascular density, functionality and permeability are not the only limitations, 
but more importantly the majority of tumor vasculature is not permeable 
to liposomes under physiological conditions [17-18, 9, 11]. Manipulation 
of tumor vasculature provides essential paths to improve anticancer drug 
delivery [19-22]. For example, approaches on normalizing tumor vasculature 
through targeting vascular endothelial growth factor (VEGF) or its receptors 
improve delivery of chemotherapeutic drugs administered in free form 
[23-25]. Alternatively, abnormalization of tumor vasculature by increasing 
vascular permeability upon administration of compounds such as TNF-α and 
histamine can also enhance the effect of chemotherapeutic compounds [26-29, 
21]. Normalization of tumor vasculature did not improve drug delivery with 
nanoparticle entrapped drug [30], whereas abnormalization using TNF-α 
strongly improved liposomal drug delivery [31, 11]. 
Local mild hyperthermia 
Mild HT may function as a physical alternative to the use of biological 
modifiers to increase tumor vasculature permeability. Regarding improved 
delivery of liposomal drugs, mild HT can increase permeability of tumor 
vasculature, thus increase intratumoral liposomal drug accumulation [32-35]. 
Moreover, mild HT increases tissue perfusion and extravascular fluid flow 
in the heated volume, therefore may facilitate liposomal drug penetration 
in solid tumors [36-37]. Additionally, vasculature endurance towards HT is 
suggested to be lower in tumor tissue compared to normal tissues, rendering 
increased specificity of liposomal drug delivery to tumors [38]. HT increases 
perfusion and tissue oxygenation, elevates interstitial microconvection and 
fluid flow, inhibits DNA repair, as well as sensitizes cancer cells towards 
chemotherapeutic compounds [36, 39-41]. Therefore, local mild HT at solid 
tumors can contribute to improved liposomal chemotherapy via several 
mechanisms. 
Mild HT of 39-43°C is clinically applied as an adjuvant to chemotherapy 
and radiotherapy to improve the therapeutic outcome and used to treat 
various tumors, e.g. melanoma, sarcoma, breast cancer, cervix cancer, and 
head and neck cancer [42-43]. Van der Zee et al. reported that HT improved 
the clinical outcome of standard radiotherapy for locally advanced bladder, 
cervix and rectum tumors [42]. The first randomized phase III clinical trial on 
combination of chemotherapy and HT proved that regional HT increased the 
14
Introduction
benefit of chemotherapy in high grade soft-tissue sarcoma [43]. Clinical mild 
HT is routinely scheduled for 1 hour after reaching a steady hyperthermic 
temperature to maximize the synergistic effect [42, 44]. During clinical 
application, catheter installed thermometers or more recently magnetic 
resonance imaging (MRI) thermometry, are employed to monitor tissue 
temperature in time. Although reaching mild hyperthermic temperatures in 
a tumor depends on tumor size, location, perfusion, treatment planning and 
imaging, the available equipment nowadays allows for increasingly precise 
heating of a defined tissue volume up to 43°C using external microwave or 
high intensity focused ultrasound (HIFU) [45-47].  
Thermosensitive liposomes 
Design of liposomes has been focused on improving functionality or 
increasing targeting. To do so, novel lipids have been introduced to optimize 
liposome characteristics [48]. Targeting of liposomes is improved for instance 
by attaching e.g. cationic charges or antibodies on the liposome membrane 
to recognize tumor-specific sites [49-52]. Another alternative approach to 
improve liposomal chemotherapy delivery emphasizes on triggered drug 
release from liposomes accumulated in tumors. In this thesis, thermosensitive 
liposomes (TSL) and local mild hyperthermia (HT) are employed as means to 
further advance liposomal chemotherapy. TSL are nanovesicles composed of 
a temperature sensitive phospholipid-based membrane, which features a gel-
to-liquid crystalline phase transition at its membrane melting temperature 
(Tm) tailored around temperatures achievable by mild (HT) [53]. In the core 
of TSL, hydrophilic compounds can be entrapped; while in the membrane 
of TSL, hydrophobic molecules can be embedded. At Tm, trans to gauche 
conformational changes increase the mobility of phospholipids, rendering 
the fluidized TSL membrane more permeable towards water and solutes 
[54]. Therefore, hydrophilic compounds can be released from the TSL. 
When a single-chain phospholipid, lysolecithin, is incorporated in the TSL 
membrane, rapid release of contents is further enhanced through formation 
and evolution of porous defects when the temperature is approaching Tm 
[55-57]. Tagami, et al. introduced Brij surfactants to replace lysolecithin and 
DSPE-PEG2000, and maintained stability and release kinetics at similar levels to 
lysolecithin-based TSL [58]. Alternatively, Lindner et al. reported inclusion of 
a novel phospholipid, 1,2-dipalmitoyl-sn-glycoero-3-phosphoglyceroglycerol, 
which in replacement of DSPE-PEG2000 was able to ensure long circulation 
of TSL as well as contribute to enhanced drug release around the Tm of the 
TSL membrane [59]. Optimization of TSL formulation, in terms of drug 
encapsulation efficiency, stability at physiological temperature and release 
kinetics at mild HT will undoubtedly further enhance the unique features of 
TSL for an advanced TSL-mediated drug delivery to disease sites. 
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Aim of the thesis 
The aim of the work described in this thesis is to improve intratumoral 
liposomal drug accumulation, by applying local mild HT at tumors to induce 
hyperpermeable tumor vasculature for liposomal drug extravasation and 
increased fluid flow to further facilitate liposomal drug penetration in the 
EES. After the maximal accumulation of liposomal drugs in tumors, drugs are 
actively released from liposomes to disclose their bioavailability. In order to 
achieve an active triggered drug release from the liposomes, TSL with Tm at 
mild HT are used as drug carriers. The use of mild HT focuses on two targets, 
tumor vasculature and the membrane of TSL. The correlations between mild 
HT and TSL stability and release kinetics, and between mild HT and tumor 
vasculature permeability are matters of the study. TSL formulation for rapid 
Dox release is preferred for intravascular release upon mild HT, while TSL 
formulation for slow Dox release is desirable for extravascular release upon 
two-step mild HT (see Diagram for two-step planning, interstitial drug release 
(a) vs. intravascular drug release (b)) [60-62]. 
Diagram. Schedule of mild HT in a two-step manner. Illustration of interstitial 
drug release (a) vs. intravascular drug release (b). 
Topics of the thesis  
To begin such a project, a TSL formulation that is stable at physiological 
temperature in circulation is required. Chapter 2 describes a TSL formulation 
composed of classic temperature sensitive phospholipids, omitting the lyso-
lecithin for ultrafast release, but with an optimized DSPE-PEG2000 concentration 
for stability at physiological temperature and fast release at mild HT. These 
optimized TSL ensure a prolonged content retention at physiological 
temperature when exposed to serum proteins, and also feature in vitro and 
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in vivo rapid content release at mild HT. Chapter 3 investigates the effect of 
mild HT on tumor vasculature permeability for liposome extravasation and 
intratumoral penetration. Multiple thermal doses are compared for levels of 
liposome density in the EES, penetration depth in murine and xenograft tumor 
models, covering four major models in cancer research. The heterogeneity 
of tumor vasculature permeability is compared and quantified among 
tumor models and locations of individual tumors, and demonstrated by 
computer modeling. Liposome extravasation and penetration processes are 
illustrated through intravital confocal microscopy, and intratumoral liposome 
accumulation is visualized by whole body optical imaging. Chapter 4 focuses 
on in vitro and in vivo profiling of Dox encapsulated in optimized TSL. Dox-
TSL in vitro stability and release kinetics in serum, and in vivo tumor growth 
control and survival after a single treatment of intravascular Dox release are 
compared to Dox encapsulated in lyso-lipid based TSL (Dox-LTSL), which 
is currently in clinical trials [63]. Chapter 5 proposes a novel two-step mild 
HT approach. The first-step local mild HT is for inducing permeable tumor 
vasculature, after which liposomal drugs are systemically administered 
at physiological temperature. Liposomal drugs are allowed to circulate for 
two hours, to gradually accumulate in the EES in tumors through permeable 
tumor vasculature. Then, the second-step local mild HT is applied to trigger 
extravascular Dox release from extravasated Dox-TSL. In this thesis, tumor 
growth control and survival after the two-step mild HT approach is compared 
to intravascular release approach. Chapter 6 studies the effect of heat cycling 
on tumor vasculature permeability and content release kinetics of TSL. 
Heat cycling mimics the clinical application of HIFU-based heating of large 
tumors. While HIFU is scanning through tumors, every fraction of a tumor 
is experiencing tissue heating and cooling alternately, resulting in a rather 
heterogeneous heat delivery. Through each heat cycle, contents are released 
from TSL and tumor vasculature accumulates heat stress. Heat cycling is 
studied for tumor vasculature permeability induced by heat stress, and for 
content release from TSL triggered by mild HT. The therapeutic efficacy of 
heat cycling is investigated and compared to continuous mild HT. Chapter 7 
discusses the results of the studies and reviews the current status of mild HT 
mediated drug delivery using TSL. 
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Abstract 
Liposomes are potent nanocarriers to deliver chemotherapeutic drugs to 
tumors. However, the inefficient drug release hinders their application. 
Thermosensitive liposomes (TSL) can release drugs upon heat. This study aims 
to identify the optimum 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
PEG2000 (DSPE-PEG2000) concentration in stealth TSL to improve content release 
efficiency under mild hyperthermia (HT). TSL were prepared with DSPE-
PEG2000 from 1 to 10 mol%, around 80 nm in size. Quenched carboxyfluorescein 
(CF) in aqueous phase represented encapsulated drugs. In vitro temperature/
time-dependent CF release and TSL stability in serum were quantified by 
fluorometry. In vivo CF release in dorsal skin flap window chamber models 
implanted with human BLM melanoma was captured by confocal microscopy. 
In vitro heat triggered CF release increased with increasing DSPE-PEG2000 
density. However, 6 mol% and higher DSPE-PEG2000 caused CF leakage at 
physiological temperature. TSL with 5 mol% DSPE-PEG2000 were stable at 
37°C, while released 60% CF in one minute and almost 100% CF in one hour at 
42°C. In vivo optical intravital imaging showed immediate massive CF release 
above 41°C. In conclusion, incorporation of 5 mol% DSPE-PEG2000 optimized 
stealth TSL content release triggered by HT. 
Keywords: 
Thermosensitive liposomes, hyperthermia, poly(ethylene glycol), drug 
delivery, triggered release, tumor, intravital microscopy. 
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1. Introduction 
The major obstacle of current available chemotherapy is the inability to deliver 
adequate concentration of drugs to tumors, but causes considerable systemic 
toxicity which limits their applicable dose. Most chemotherapeutic drugs are 
delivered intravenously and rapidly cleared from circulation, e.g. doxorubicin 
(Dox) has a five to ten minutes half-life in plasma [1]. Therefore, only a fraction 
of the administered dose can reach tumors. Long-circulating drug-carrying 
nanoparticles, e.g. pegylated liposomal Dox (Doxil or Caelyx), reduce toxicity 
and augment intratumoral delivery compared to free drugs [2-5]. Despite the 
prolonged circulation time and increased tumor accumulation [2, 6], slow 
and passive drug release from these liposomes hinders an optimal antitumor 
effect. Thus, it is critical to actively trigger liposomal drug release. Therefore, 
thermosensitive liposomes (TSL) [7] and local hyperthermia (HT) are used. 
This approach relies on features of tumor microvasculature and TSL. Relative 
leakiness of partial tumor vessels can cause extravasation of small liposomes 
(i.e. < 400 nm) [8-12]. Permeability of tumor microvasculature can be further 
enhanced by heat [13], causing more liposomes to accumulate intratumorally 
[14]. 
Intratumoral liposome accumulation does not guarantee drug bioavailability. 
The entrapped drugs need to be released from the liposomes to reach tumor 
cells for a therapeutic effect. TSL are phospholipid-based vesicles with a large 
capacity to encapsulate drugs and to release them upon heat. This release 
depends on temperature and lipid composition of TSL [15]. When a TSL 
lipid membrane undergoes a gel-to-liquid crystalline phase transition, it 
becomes more permeable towards water and solutes, because trans to gauche 
conformational changes increase the mobility of phospholipids [16]. In this 
way, the entrapped hydrophilic drugs can be released. 
For phospholipids with saturated hydrocarbon chains, lengths of fatty acid 
chains primarily determine the Tm, the main gel-to-liquid crystalline phase 
transition temperature of lipid membranes. For stealth non-thermosensitive 
liposomes [17, 18], the concentration of grafted 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) in lipid membrane influences 
membrane permeability [19]. Surface-grafted polymers can disturb membrane 
integrity by inducing steric repulsion between opposing polymers, e.g. DSPE-
PEG2000 and DSPE-PEG5000 [20]. Molecular structures of PEG-polymers can be 
distinguished as interdigitated mushroom, mushroom and brush regimes 
[21]. Polymer regimes are determined by distance between grafting sites, and 
by polymer sizes [21]. Kenworthy et al. suggested that 4 mol% DPPE-PEG2000 
induced maximum membrane permeability [21, 22]. 
For stealth non-thermosensitive liposomes in general, 1 – 5 mol% DSPE-
PEG2000 is commonly grafted on lipid membranes for prolonged circulation 
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time, and 5 mol% DSPE-PEG2000 is the sufficient and optimal concentration 
[17]. In addition, DSPE-PEG2000 also prevents liposome aggregation in 
plasma [23]. Formulations containing up to 10 mol% DSPE-PEG2000 have been 
described [20, 22, 24], though PEG-lipids tend to form micellar structures at 
higher concentrations [25], and disk-like micelle formation can be enhanced 
by extrusion repeatedly crossing Tm [26]. Therefore, all TSL formulations in 
this study were extruded above their Tm to avoid PEG-micelle formation. 
Stealth TSL typically adopt conventional DSPE-PEG2000 concentrations 
between 1 and 5 mol% in stealth non-thermosensitive liposomes to prolong 
half-lives in plasma for drug delivery [17, 18, 27]. However, the ideal DSPE-
PEG2000 concentration for TSL content release has not yet been determined. 
This study provides a valuable guide on the use of DSPE-PEG2000 in TSL by 
identifying the optimum DSPE-PEG2000 concentration with regard to intrinsic 
stability, in vitro and in vivo content release properties, to improve content 
release of stealth TSL triggered by mild HT. 
 
2. Materials and methods 
2.1 Chemicals 
The phospholipids 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine (DPPC), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were provided by 
Lipoid  (Ludwigshafen, Germany), and phosphatidylethanolamine-dioleoyl-
sulforhodamine B (Rho-PE) was purchased from Avanti Polar Lipid Inc. 
Carboxyfluorescein (CF) purified by recrystallization [28]. Other chemicals 
were obtained from Sigma Aldrich (Netherlands) unless otherwise specified. 
2.2 Preparation of TSL 
TSL were composed of DPPC/DSPC/DSPE-PEG2000 in a molar ratio of 80:(20-
x):x (x = 1, 3, 4, 5, 6, 10). TSL < 100 nm in diameter were prepared by lipid film 
hydration and extrusion method at 60°C (thermobarrel extruder, Northern 
Lipids, Vancouver, Canada) [29]. Quenched CF (100 mM) at pH 7.2 was 
encapsulated in the aqueous phase, and 0.1 mol% Rho-PE was incorporated 
in the liposome bilayer. Unencapsulated CF was removed by gel filtration 
through PD-10 columns (GE Healthcare, Buckinghamshire, UK). Size and 
polydispersity index (PDI) were determined by dynamic light scattering 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Lipid 
concentration was measured by phosphate assay [30]. 
2.3 Differential scanning calorimetry 
Tm was measured by a Capillary Cell MicroCalorimeter (MicroCal VP-DSC) 
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[31]. 
2.4 Stability and encapsulation capability 
TSL in vitro membrane stability in serum was tested by exposure to 90% serum 
for one hour. CF leakage was detected by fluorometry [28]. Encapsulation was 
determined by TSL exposure to detergent to receive maximal CF fluorescence. 
A TSL suspension (1 mM [lipid]) and pre-heated fetal calf serum (FCS) (37°C) 
were mixed at 1:9 (v/v). The mixture was then incubated at 37°C for one hour 
in a thermal-shaker (Eppendorf Thermomixer) at 300 rpm. After incubation, 
samples were diluted in 10 mM Tris/NaCl 0.9% at pH 8.0 at 1:50 (v/v) (It), 
and measured by fluorometry at Ex. 493 nm / Em. 513 nm (Hitachi F-4500 
Fluorescence Spectrophotometer). Samples without incubation were measured 
as negative controls (I0). Samples in the replacement of FCS to detergent (2% 
Triton X-100 in H2O) were incubated at 55°C for 30 minutes at 1400 rpm and 
measured as positive controls (I∞). Positive controls were adjusted to contain 
identical amounts of FCS. CF release was calculated as CF (%) = (It – I0)/(I∞ – I0)
x100 [28]. TSL stability was determined as Stability (%) = 100 – CF (%). TSL 
stability at 4 and 25°C was determined in the same way. TSL encapsulation 
was calculated as Encapsulation ratio (CF/lipid) = [CF]/[lipid]. 
2.5 Temperature-dependent CF release 
Temperature influence on in vitro TSL content release rate in 90% FCS was 
determined. Samples were measured after five minutes incubation at desired 
temperatures from 37 to 45°C and CF release (%) was calculated as above 
(2.4). 
2.6 Time-dependent CF release 
In vitro TSL content release over time was monitored online by fluorometry. 
The optimal temperature achieved from temperature-dependent CF release 
experiments was adopted for time-dependent CF release experiments. A TSL 
suspension (1 mM [lipid]) and pre-heated FCS were mixed 1:150 (v/v) under 
stirring. CF release was measured online for one hour (Ex. 493 nm / Em. 513 
nm). Then samples were added with 10% Triton X-100 151:1 (v/v) as positive 
control. Samples without heating were measured as negative controls. CF 
release (%) was calculated as above (2.4).  
2.7 Animal models 
NMRI nu/nu mice were purchased from Charles River and housed at 20 – 22°C, 
humidity of 50 – 60%, and 12 hour light-dark cycles. Sterile rodent food and 
acidified vitamin C-fortified water were given ad libitum. Eight-week old mice, 
weighing 20 – 25 g were used. All animal studies were done in accordance 
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with protocols approved by the committee on Animal Research of Erasmus 
MC, Rotterdam, the Netherlands.
2.8 In vivo tumor models and content release 
BLM cells were cultured in DMEM medium (Lonza, Belgium) containing 10% 
(v/v) FCS, and incubated at 37°C in a humidified environment of 95% air and 
5% CO2. 10
6 tumor cells were injected subcutaneously in flanks of mice, and 
bulk tumors of 10 mm in diameter were used. 
In vivo CF release was observed by intravital fluorescence microscopy on 
dorsal skin flap window chamber models in mice implanted with human 
BLM melanoma [32, 33]. Models were used for experiments within two weeks, 
when tumor size reached 4 – 6 mm in diameter. Mice were anesthetized with 
isofluorane (Nicholas Piramal, London, UK) and placed on a thermal stage 
at 37°C during experiments. Homogenous local HT was provided by an 
external circular resistive electric heating coil attached to glass at the back side 
of the window chamber. Thermocouples (point-welded thin manganese and 
constantane wires, H. Drijfhout & Zoon’s edelmetaalbedrijven, Amsterdam) 
were inserted in window chambers to monitor tissue temperature. Two µmol 
lipids of TSL with 5 mol% DSPE-PEG2000 with Rho-PE and CF labeling were 
injected intravenously through the tail vein. 
Regions of interest were selected by confocal microscopy (Zeiss LSM 510 
META). Background images were captured before TSL injection. Imaging was 
started within 10 minutes post-injection. CF release was monitored online by 
a 488 nm argon laser and Rho-PE was detected by a 543 nm Helium-Neon 
laser. Window chamber tissue was heated up to 42°C and remained for five 
minutes before cooling down to 37°C and maintained for 10 minutes. Images 
of transmission channel and fluorescent channels (x 10 objective lens, 284 
µm pinhole) were recorded intermittently at each temperature point from 39 
to 42°C, and at 1, 2, 3, 4, 5 minutes after tissue temperature reached 42°C, 
and end points of experiments after tissue temperature was down to 37°C. 
Images of 512 x 512 pixels were analyzed with a Zeiss image program (LSM, 
Germany). CF release was quantified as Area (mm2) x Average Intensity at 
150 – 255 threshold by Image J (Wayne Rasband, National Institutes of Health, 
USA). As additions to the same experimental models, images (x 10 objective 
lens) were also taken every 18 seconds throughout experiments and converted 
to videos by Image J. 
2.9 Statistical analysis 
All in vitro data were represented as mean ± standard error of the mean (SEM) 
of triplicate samples from three independent experiments. In vitro TSL CF 
release were compared through temperature-dependent CF release study, 
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and analyzed by nonparametric Mann-Whitney test. 
3. Results  
3.1 Characterization of the TSL 
In vitro characteristics of the TSL are summed up in Table 1. TSL encapsulation 
ratio of CF/lipid (mole/mole) of the different formulations was comparable 
except for TSL with 10 mol% DSPE-PEG2000, which was significantly lower 
than any other formulation (p value ≤ 0.05). TSL with 1 – 5 mol% DSPE-PEG2000 
in 90% serum retained over 96% CF and TSL with 6 mol% DSPE-PEG2000 
retained 91% CF, while TSL with 10 mol% DSPE-PEG2000 were the least stable 
to retain 83% CF after one hour incubation at 37°C. Size of the TSL was around 
80 nm, PDI < 0.1. Tm of the TSL was identical at 43°C (supplementary Fig. 1). 
TSL lacking DSPE-PEG2000 (0 mol%) were instable after preparation (data not 
shown), and therefore could not be tested. 
Table 1: TSL characteristics 
* Nonparametric Mann-Whitney test, p value ≤ 0.05, a mean ± SEM, N = 3. 
3.2 Temperature-dependent CF release 
Temperature-dependent CF release of the TSL was measured after 5 minutes 
incubation in 90% serum and is represented in Fig. 1. TSL with different PEG-
densities were all stable up to 38°C, with CF leakage < 2%. TSL slowly started 
to release CF at 39°C, except for TSL with 10 mol% DSPE-PEG2000, which 
already released more than 15% CF in five minutes. TSL with 1 – 5 mol% 
DSPE-PEG2000 reached their highest CF release levels at 42°C, while TSL with 6 
and 10 mol% DSPE-PEG2000 shifted their highest release levels to 43°C though 
not significant compare to 42°C (6 mol% DSPE-PEG2000, p value = 0.827; 10 
mol% DSPE-PEG2000, p value = 0.275). For all TSL, CF release levels decreased 
gradually from 43 to 45°C. In general CF release increased with increasing 
PEG-density. TSL with 5 mol% DSPE-PEG2000 showed the highest release 
level amongst stable TSL with 1 – 5 mol% DSPE-PEG2000 (p value ≤ 0.05). The 
difference in release levels between TSL with 5 and 6 mol% DSPE-PEG2000 was 
negligible at up to 42°C. There was no CF leakage from any TSL at 4 or 25°C 
(data not shown). 
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Fig. 1: In vitro CF release from TSL with different PEG-densities, 1 mol% (◊), 
3 mol% (□), 4 mol% ( ), 5 mol% (   ), 6 mol% ( ), and 10 mol% (●), measured 
after five minutes incubation at indicated temperatures in 90% serum. 
TSL with 1 – 5 mol% DSPE-PEG2000 were stable up to 38°C and show maximal 
release at 42°C. TSL with 5 mol% DSPE-PEG2000 showed significantly higher 
release level than stable TSL containing 1 – 4 mol% DSPE-PEG2000 at 40 – 43°C. 
* Nonparametric Mann-Whitney test, p ≤ 0.05, N = 3.
3.3 Time-dependent CF release 
In vivo time-dependent CF release at 42°C in 99.7% serum was monitored 
online for one hour (Fig. 2 A). TSL with 5 mol% DSPE-PEG2000 released CF faster 
than TSL with lower PEG-densities, and boosted CF release over 3-fold of the 
level of TSL with 1 mol% DSPE-PEG2000. More than 60% CF was effectively 
released from TSL with 5 mol% DSPE-PEG2000 in the first minute (Fig. 2 B). 
Almost 100% CF was released in one hour (Fig. 2 A and Table 2). CF release 
levels were comparable amongst TSL with 5, 6, and 10 mol% DSPE-PEG2000. 
Comparing Fig. 1 and 2 B, CF release of TSL after five minutes incubation 
was higher in time-dependent than in temperature-dependent CF release 
experiments, likely due to increased FCS concentration (90 to 99.7%). Serum 
protein components are involved in membrane instability. 
Table 2: TSL characteristics on CF release
a mean ± SEM, N = 3.
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Fig. 2 A: In vitro CF release in time from TSL with different PEG-densities, 1 
mol% (◊), 3 mol% (□), 4 mol% ( ), 5 mol% ( ), 6 mol% ( ), and 10 mol% (●), 
measured at indicated time after placing TSL at 42°C in 99.7% serum. Rapid 
release occurred in the first few minutes. TSL with 5 mol% DSPE-PEG2000 
released comparable amount of CF to TSL with 6 or 10 mol% DSPE-PEG2000 
and reached their maximal release in one hour (N = 3). B: Kinetics of in vitro 
CF release from TSL with different PEG-densities in the first five minutes 
measured at indicated time after placing TSL in 99.7% serum at 42°C. Rapid 
CF release occurred in the first minute, N = 3. 
3.4 In vivo CF release 
In vivo CF release of TSL was studied by intravital optical imaging using dorsal 
skin fold window chamber models implanted with human BLM melanoma 
(Fig. 3 and supplementary video). Functioning tumor vessels were visualized 
by Rho-PE labeled TSL with 5 mol% DSPE-PEG2000, and no CF leakage was 
observed up to 39.5°C (Fig. 3 B). TSL slowly released CF at 40°C (Fig. 3 C), and 
massively released CF within seconds when tissue temperature was reaching 
42°C. Free CF diffused into interstitial space (Fig. 3 D – F and supplementary 
video), but CF release was shut down immediately when tissue temperature 
was decreasing to 37°C (Fig. 3 G). Free CF was quickly washed out from tumor 
tissue, with almost no remaining within 12 minutes at 37°C (Fig. 3 H). Tissue 
temperatures were recorded online (Fig. 4) and the letters correspond to Fig. 
3 images. Tissue temperature increased from 37°C to 42°C in 15 minutes, 
remained at 42°C for five minutes, and then decreased to 37°C in five minutes. 
Quantified CF release was negligible up to 40°C (Fig. 5), while elevated steeply 
to almost two-fold (180 x 106 vs. 100 x 106) (Area (mm2) x Average Intensity) 
in five minutes at 42°C. Decreasing temperature shut down CF release back 
to baseline. 
222
Li et al. / Journal of Controlled Release 143 (2010) 274-279
Fig. 3: In vivo CF release from TSL with CF in aqueous phase and Rho-PE 
labeled lipid membrane. Images are presented as merged green (CF) and red 
(Rho-PE) fluorescence (x 10 objective lens, N = 3) A, Ttissue = 37°C post-injection; 
B, Ttissue = 39.5°C; C, Ttissue = 40°C; D, Ttissue = 42°C; E, Ttissue = 42°C in one minute; 
F, Ttissue = 42°C in five minutes; G, Ttissue = 37°C; H, Ttissue = 37°C in 12 minutes. 
Bar, 500 µm. 
Fig. 4: Online monitoring of tissue temperature. A – H correspond with the 
images in Fig 3.
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Fig. 5: Quantification of in vivo CF release in Fig. 3. Primary Y-axis represents 
Area (mm2) x Average Intensity x 106 (●) as mean ± SD. Secondary Y-axis 
represents corresponding tissue temperatures ( ). 
4. Discussion  
Stealth TSL with 5 mol% DSPE-PEG2000 were optimal, considering stability 
at 4, 25, 37°C and release kinetics at mild HT. Stealth TSL with 1 – 5 mol% 
DSPE-PEG2000 were stable (< 4% CF leakage) at 37°C in 90% serum, while TSL 
with 6 and 10 mol% DSPE-PEG2000 leaked out 9 and 17% CF, after one hour 
incubation. High DSPE-PEG2000 density, especially 10 mol%, collapsed the 
membrane integrity, causing content leakage at relatively low temperatures. 
Based on in vitro stability study of stealth TSL (Table 1), 1 – 5 mol% DSPE-
PEG2000 can sufficiently stabilize lipid membrane in 90% serum at physiological 
temperature, known as the major effect of DSPE-PEG2000 [17, 18]. Noticeable 
CF release started at 40°C in both in vitro and in vivo experiments. Remarkable 
in vitro CF release occurred between 42 and 43°C, which is consistent with 
their Tm. Increase of DSPE-PEG2000 density from 1 to 4 mol% diminishes 
the distance between grafting sites for mushroom regime, while increase 
of DSPE-PEG2000 density from 4 to 5 mol% forces the mushroom-to-brush 
transition. We speculate the structural heterogeneity of DSPE-PEG2000 
destabilizes lipid membrane at around Tm, causing increased content release. 
More importantly, DSPE-PEG2000-density strikingly modified the permeability 
of lipid membranes against temperature for hydrophilic content release. By 
contrast, Tm of the TSL remained intact (Table 1). Five mol% DSPE-PEG2000 
noteworthily enhanced TSL release kinetics, compared to lower densities (Fig. 
1). Above Tm, membrane phospholipids likely reached a more homogeneous 
liquid crystaline phase, causing decreased CF release. At 42°C, TSL with 5 
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mol% DSPE-PEG2000 released over 60% CF in one minute, and almost 100% in 
one hour. Destabilization of the lipid membrane with 10 mol% DSPE-PEG2000 
caused significant release at 37°C, and it may play a more important role than 
change of membrane modality for content release. Additionally, TSL with 
10 mol% DSPE-PEG2000 showed 3-fold lower encapsulation compared to 5 
mol% DSPE-PEG2000. Therefore, our study concludes that the optimum DSPE-
PEG2000 concentration to use in stealth TSL is 5 mol%. Retention of CF, which 
is commonly used as a fluorescent test molecule for low molecular weight 
hydrophilic drugs, may not be predictive of drug molecules. For each new 
TSL-drug formulation stability and release kinetics need to be determined. 
Encouragingly, lysolipid-based Dox-containing low TSL (Dox-LTSL) in 
combination with local HT have showed promising efficacy [34] and are 
currently in clinical trials [35]. Dox-LTSL is composed of DPPC/MPPC/DSPE-
PEG2000 in a molar ratio of 90:10:4, meaning 3.8 mol% DSPE-PEG2000. Although 
the content release mechanism of lysolecithin-containing TSL may differ from 
lysolecithin-free TSL, higher DSPE-PEG2000 density (i.e. 5 mol%) in the lipid 
membrane can still facilitate Dox-LTSL drug release by forcing phospholipid 
monolayers apart [36] to create more space for proton exchange across 
the membrane, causing the pH gradient to collapse, which in return eases 
doxorubicin cross-membrane penetration. On the other hand, traditional 
TSL is composed of DPPC/HSPC/cholesterol/DSPE-PEG2000 in a molar ratio 
of 100:50:30:6, meaning 3.2 mol% DSPE-PEG2000. These Dox-encapsulated 
cholesterol-containing TSL released ~ 60% Dox in vitro in 50% plasma in 30 
minutes [37]. Gaber, et al. [37] also concluded from their study that cholesterol 
shielded TSL thermosensitivity, while DSPE-PEG2000 not only protected TSL in 
plasma but also revealed their thermosensitivity. Therefore, it appears to be 
undoubtedly beneficial to increase DSPE-PEG2000 concentration in cholesterol-
containing TSL to 5 mol%.  
According to literature, we standardized TSL size to be smaller than 100 
nm, to ultimately enhance intratumoral liposomal drug accumulation by 
liposome extravasation through tumor microvasculature [38]. Several groups 
demonstrated that 100 nm liposomes extravasate much easier than 200 or 
400 nm liposomes [12, 32, 38]. Moreover, small liposomes can diffuse better 
throughout tumor tissue to avoid limited perivascular accumulation. It is 
practical to expect greater drug encapsulation in larger TSL (e.g. 200 nm), 
which might lead to higher content release. Nevertheless, our 100 nm TSL 
showed compatible release rates, compared with 170 nm PEG-free TSL, DPPC/
DSPC/DPPGOG in a molar ratio of 5:2:3 [39]. 
In conclusion, incorporation of 5 mol% DSPE-PEG2000 in the lipid membrane 
optimized stealth TSL content release triggered by mild HT (~ 42°C). In vivo 
tumor models confirmed these in vitro TSL release characteristics. These 
TSL will be employed with local HT to achieve both maximal intratumoral 
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liposomal drug accumulation and rapid triggered drug release. The superior 
application of stealth TSL and local HT has the potential to aid liposomal 
chemotherapy in clinical practice. 
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Abstract
Accumulation of nanoparticles in solid tumors depends on their extravasation. 
However, vascular permeability is very heterogeneous within a tumor and 
among different tumor types, hampering efficient delivery. Local hyperthermia 
at a tumor can improve nanoparticle delivery by increasing tumor vasculature 
permeability, perfusion and interstitial fluid flow. The aim of this study is to 
investigate hyperthermia conditions required to improve tumor vasculature 
permeability, subsequent liposome extravasation and interstitial penetration 
in 4 tumor models. Tumors are implanted in dorsal skin flap window chambers 
and observed for liposome (~85 nm) accumulation by intravital confocal 
microscopy. Local hyperthermia at 41°C for 30 minutes initiates liposome 
extravasation through permeable tumor vasculature in all 4 tumor models. 
A further increase in nanoparticle extravasation occurs while continuing 
heating to 1 hour, which is a clinically relevant duration. After hyperthermia, 
tumor vasculature remains permeable for 8 hours. We visualize gaps in the 
endothelial lining of up to 10 µm induced by HT. Liposomes extravasate 
through these gaps and penetrate into the interstitial space to at least 27.5 µm 
in radius from vessel walls. Whole body optical imaging confirms HT induced 
extravasation while liposome extravasation was absent at normothermia. In 
conclusion, thermal dose of 41°C for 1 hour is effective to induce long-lasting 
permeable tumor vasculature for liposome extravasation and interstitial 
penetration. These findings hold promise for improved intratumoral drug 
delivery upon application of local mild hyperthermia prior to administration 
of nanoparticle-based drug delivery systems. 
Keywords: 
Liposome extravasation, mild hyperthermia, hyperpermeable 
tumorvasculature, nanoparticle drug delivery, intravital confocal microscopy, 
whole body optical imaging. 
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1. Introduction 
Conventional chemotherapy relies on systemic delivery of cytotoxic drugs. 
However, intratumoral drug concentration is low, while toxicity to healthy 
tissues is dose-limiting. Tumor vasculature manipulation provides a mode to 
improve anticancer drug delivery [1-3]. 
Nanoparticle-based chemotherapeutic drug delivery reduces systemic 
toxicity of the encapsulated drug, improves drug retention in circulation, and 
increases intratumoral drug concentration [4-8]. The drug delivery mechanism 
involves nanoparticle extravasation through permeable tumor vasculature and 
deposition of drugs into the interstitial space in tumors [9-10]. However, due 
to nanoparticle size, limited interstitial fluid flow and the compact nature of 
the interstitial matrix in tumors, nanoparticle penetration in the extravascular 
extracellular space (EES) is limited [11-12]. Only a fraction of the tumor 
vessels are permeable inflicting a poor and rather heterogeneous delivery 
of nanoparticles [13, 10]. Both heterogeneous extravasation and limited 
intratumoral nanoparticle penetration leave room for further improvement of 
nanoparticle-based drug delivery.
Normalization of tumor vasculature does not improve liposomal drug 
delivery, while abnormalization using TNF-α strongly improved liposome-
based drug delivery [14-16]. Mild hyperthermia (HT) may function as a 
physical alternative to increase tumor vasculature permeability. Mild HT 
is used in combination with chemotherapy or radiotherapy [17-18]. The 
first randomized phase III clinical trial proving that regional hyperthermia 
increased the benefit of chemotherapy in high grade soft-tissue sarcoma 
has been reported by Issels’ group [19]. Regarding improved delivery of 
nanoparticles, the HT-induced hyperpermeability of tumor vasculature can 
increase nanoparticle extravasation [20-22]. Kong et al. pioneered the use of 
mild HT on nanoparticle extravasation [21-22]. Local mild HT increased the 
pore size in tumor vasculature, decreased steric and hydrodynamic hindrances, 
therefore elevating the intratumoral interstitial fluid flow and pressure to 
facilitate extravascular nanoparticle (~125 nm in diameter) penetration [23]. 
Additionally, vasculature endurance towards heat is lower in tumor tissues 
compared to normal tissues, rendering increased specificity of nanoparticle 
delivery in tumors [24]. 
We investigated the HT conditions required to improve the intratumoral 
delivery of liposomes as the first step towards improved drug delivery. We 
also made use of optimized thermosensitive liposomes (TSL), which enable a 
triggered drug release upon mild HT [25]. The ultimate purpose is to apply 
thermosensitive liposomes in combination with mild HT in a two-step manner 
(see diagram). HT to induce liposome extravasation will be applied as the 
first step. We show that the observed enhanced permeability and retention 
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(EPR) of liposomes upon HT benefits drug delivery, but it has to be taken into 
account that entrapment of the drug in, and release from the liposomes are 
crucial steps, which co-determine final accumulation of the active compound 
at the target site. The second HT step is to force release of the encapsulated 
drug, making it bioavailable.
Diagram. Schedule of mild HT in a two-step manner. 
2. Materials and methods  
2.1. Lipids and chemical reagents 
The phospholipids 1,2-dipalmityol-sn-glycero-3-phosphocholine (DPPC), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were from Lipoid 
GmbH (Ludwigshafen, Germany). 3-(2-pyridyl)-dithiopropionyl-PEG-DSPE 
(PDP-PEG-DSPE) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (Rho-PE) were purchased from Avanti Polar 
Lipid Inc. IRDye 800CW Maleimide infrared dye was from LI-COR Biosciences. 
Dulbecco’s modified eagle media (DMEM media) and fetal calf serum (FCS) 
were obtained from Sigma Aldrich (Netherlands) unless otherwise specified. 
2.2. Liposomes 
Liposomes were composed of DPPC/DSPC/DSPE-PEG2000 in a molar ratio 
of 80:15:5 [25]. Liposomes were labeled with 0.1 mol% Rho-PE in the lipid 
membrane [25]. For the optical imaging study of liposome localization in 
s.c. tumors in mice, liposomes were prepared with 1% PDP-PEG-DSPE 
to conjugate the IRDye 800CW Maleimide (molar ratio of 1:0.5). Size and 
polydispersity index (PDI) of samples at 10 – 50 µM [lipid] were determined 
by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). Lipid concentration was measured by phosphate assay 
[26]. Liposome stock of 40 mM [lipid] at size of ~85 nm in diameter with PDI 
< 0.1 were used for all experiments. 
2.3. In vivo tumor models and animal models  
Murine B16 melanoma, BFS-1 sarcoma, Lewis Lung Carcinoma (LLC) and 
human BLM melanoma cells were cultured (Greiner Bio-One, the Netherlands) 
in DMEM medium (Lonza, Belgium) containing 10% (v/v) FCS, and incubated 
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at 37°C in a humidified environment of 95% air and 5% CO2. C57BL/6 mice 
were used for murine B16 melanoma, BFS-1 sarcoma, and LLC carcinoma 
models. NMRI nu/nu mice were used for human BLM melanoma model. All 
mice were purchased from Charles River and housed at 20-22°C, humidity 
of 50-60%, and 12 hour light-dark cycles. Sterile rodent food and acidified 
vitamin C-fortified water were given ad libitum. Eight-week old mice at weight 
of 20-25 g were used. C57BL/6 mice with constitutive vascular endothelial 
cell expression of an eNOS-Tag-GFP (green fluorescent protein) fusion protein 
were developed by Dr. R. de Crom and R. van Haperen, Department of Cell 
Biology, Erasmus MC, Rotterdam, the Netherlands, bred in-house. All animal 
studies were done in accordance to protocols approved by the committee 
on Animal Research of Erasmus MC, Rotterdam, the Netherlands. General 
methods to prepare a dorsal skin flap window chamber model is to inject 
tumor cells (106) subcutaneously in flanks of mice, and bulk tumors of 1 cm in 
diameter are used for transplantation. A small viable tumor piece (~1 mm3) is 
removed from the bulk tumor and transplanted in the fascia of a dorsal skin 
flap placed in a window chamber in mice [25]. After tumor transplantation, 
mice carrying window chambers are housed individually at 30°C and 60% 
humidity. For whole body optical imaging, a tumor piece (~3 mm3) of human 
BLM melanoma was transplanted subcutaneously in the hind leg of NMRI 
nu/nu mice. Mice were used for experiments, when tumors reached ~5 mm in 
diameter in dorsal skin flap window chamber models and ~7 mm in diameter 
in s.c. models. 
2.4. Intravital confocal microscopy 
2.4.1. General experimental setup
In vivo liposome extravasation was studied by intravital fluorescence 
microscopy. Models were used in two weeks when tumor size reached ~5 
mm in diameter. Mice were anesthetized with isofluorane (Nicholas Piramal, 
London, UK) and placed on a thermal mattress at 37°C during experiments. 
An external circular resistive heating coil was attached to the glass at the 
back side of the window chamber to provide homogenous local HT [25]. 
Thermocouples (point-welded thin manganese and constantan wires, 
Thessco®, Amsterdam) were imbedded in window chambers to monitor 
tissue temperature online. Liposomes at a dose of 6 µmol lipid labeled 
with fluorescent Rho-PE were injected intravenously through the tail vein. 
Liposomes were given prior to HT, except when duration of tumor vessel 
permeability after HT was determined (see session 2.4.5.). Regions of interest 
were selected by confocal microscopy (Zeiss LSM 510 META). Background 
images were captured before liposome administration. Amplifier offsets for 
both GFP and Rho-PE were adjusted to intensity 0 when the lasers were off 
for initial image calibration. Imaging was started within 20 minutes post-
administration. Liposome extravasation was monitored online by a Helium-
334
Li et al. / Journal of Controlled Release, in press
Neon laser (543 nm), and constitutive GFP-expressing endothelial cells were 
visualized by an argon laser (488 nm). Fluorescent channels (BP 505-550 LP 
585, Plan-Neofluar 10x/0.3 lens) were recorded in 40 µm thin single images 
and 120 µm thick Z-stack before and after HT. Intermittent images were taken 
every 5 minutes during heating, HT at 41°C and resting after HT. Images with 
higher magnifications (Plan-Neofluar 20x/0.5 lens, with optical slice thickness 
of 6 µm) were taken at the end of the experiments to image discontinuous 
endothelial lining in permeable tumor vasculature. Images of 1024x1024 
pixels were analyzed with LSM image software (Zeiss, Germany). All images 
are presented at their original quality without any modification. The images 
on in vivo liposome extravasation kinetics were converted to videos by Image 
J (Wayne Rasband, National Institutes of Health, USA). 
2.4.2. Determine optimal thermal dose 
Pre-selection of an optimal thermal dose was performed in murine B16 
melanoma, BFS-1 sarcoma and LLC carcinoma in C57BL/6 mice. Window 
chamber tissues were heated up to 41°C in 10 minutes and remained for 30 
minutes (3.75 CEM43 (Cumulative Equivalent Minutes at 43°C)) or 1 hour (7.5 
CEM43), followed by resting without HT (temperature decreased down to 
30°C in ~15 minutes). Liposome extravasation through tumor vasculature was 
quantified and compared between thermal dose of 41°C for 30 minutes and 
41°C for 1 hour. Thermal dose which induced more liposome extravasation 
was selected for the following experiments. 
2.4.3. A pilot-study on delta T (temperature) on intratumoral liposome 
accumulation 
Tumors in dorsal skin flap window chamber models in mice have a baseline 
temperature of ~30°C, while s.c. tumors in mice mostly have a physiological 
temperature of 37°C. In order to evaluate whether an absolute temperature or 
temperature elevation from baseline causes vasculature hyperpermeability, 
we determined permeability at 37°C which would be an increase of 7°C over 
the baseline (~30°C). 
2.4.4. Compare liposome extravasation in different tumors 
Murine B16 melanoma, BFS-1 sarcoma and LLC carcinoma in C57BL/6 mice, 
and human BLM melanoma in NMRI nu/nu mice, were selected to measure 
liposome intensity and penetration depth during defined time courses at 
thermal dose of 41°C for 1 hour. Seven to 12 locations within a tumor were 
recorded throughout the experiments to compare liposome extravasation 
levels. 
2.4.5. Determine the duration of liposome-permeable vessels after HT 
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Liposome administration was performed at pre HT, or 4, 8, 24 hours post-HT 
in murine B16 melanoma to study the duration of permeable tumor vessels 
after a thermal dose of 41°C for 1 hour. 
2.5. In vivo whole body optical imaging of liposome localization in s.c. tumors
In order to find out the correlation between liposome extravasation and 
systemic clearance, we followed intratumoral liposome accumulation over 
time in s.c. tumors under whole body imaging. Mice were transplanted with 
s.c. human BLM melanoma in their right hind leg. Mice were anesthetized, 
and the tumor bearing hind legs were covered in aquasonic ultrasound 
gel (Parker Laboratories, Inc.) to ensure efficient heat transfer to the tumor 
surface, surrounding tissues and muscles were protected by a syringe. The 
hind legs were maintained inside of the syringes and fixed onto a rack to 
ensure a steady position in a water-bath during the HT treatment. Tumor 
temperature was monitored by a thermocouple probe, which was placed on 
the tumor and attached to an electrical thermometer. The tumor temperature 
was maintained at 41°C for 1 hour (it took ~10 minutes to increase the tumor 
temperature to 41°C). After HT, mice rested at room temperature (25°C) for 
10 minutes, after which 1 µmol of IRDye 800CW Maleimide-TSL was injected 
through a tail vein. Mice were anesthetized before imaging with the IVIS 
Spectrum (threshold set at min. 1.5x107 and max. 4x108 radiant efficiency) 
(Caliper Life Sciences, Perkin Elmer) at 0, 1, 2, 4, 24 and 48 hours post-injection. 
Background images were taken pre-HT and pre-injection. The fluorescence 
images were retrieved (Ex. 500 nm (background) and 745 nm and Em. 800 
nm) and analyzed using Living Image 4.2 software (Caliper Life Sciences). To 
determine the tumor-to-background ratio (TBR), the tumor was set as a region 
of interest and compared to an equal size region of interest placed on an area 
with background values within the mouse.  
2.6. Quantitative image analysis 
In vivo liposome extravasation through tumor vasculature upon local mild 
HT was quantified by image processing methods below in software Matlab, 
MeVisLab and ImageJ. Motion compensation was performed by geometrical 
transformation between images in each time series. Intravascular regions 
were identified from images taken immediately following injection of 
liposomes, and initial intravascular fluorescence liposome intensity was 
used for normalization of extravascular intensity. Change in normalized 
extravascular fluorescence over time was calculated to quantify extravasation. 
Vessel distance maps were then generated by Euclidean distance transfer, and 
average liposomal fluorescence intensity calculated depending on distance 
to closest vessel [13]. Due to the typical vessel distance in the range of < 
100 µm, penetration analysis up to 55 µm (half-way between vessels) was 
336
Li et al. / Journal of Controlled Release, in press
performed. Liposome penetration during HT was visualized by surface plots. 
Extravascular fluorescence liposome intensity was normalized via dividing by 
initial average intravascular intensity after administration of liposomes pre-
HT. The total percentage of tumor vascular surface (in the field of view) which 
responded to the thermal dose of 41°C for 1 hour and became permeable after 
the HT was identified and calculated for each tumor type. When extravascular 
intensity adjacent to a vessel was same or above average intravascular 
intensity (mean over all intravascular regions), the tumor vascular surface 
was considered permeable. 
Liposome extravasation post-HT at 4, 8, 24 hours was quantified by ImageJ. Real 
time intravascular liposome intensity was subtracted to obtain extravascular 
liposome intensity over time. 
2.7. Statistics 
The quantification of intravital confocal data are represented as mean ± 
standard error of the mean (SEM) of 3 mice per group. The quantification of 
whole body optical imaging and liposome accumulation in s.c. tumors are 
presented as mean ± standard deviation (SD) of 3 mice per group. Extravasated 
liposome intensity over time amongst four tumor models are analyzed by 
F-test and Kruskal-Wallis test, followed for pair wise comparison by Mann-
Whitney test with Bonferroni correction (p-value ≤ 0.05). The total percentage 
of permeable tumor vascular surface after HT and liposome intensity over 
time after administration at 4, 8, 24 hours post-HT were analyzed for pair wise 
comparison by Mann-Whitney test (p-value ≤ 0.05). 
3. Results 
3.1. Increased liposome extravasation after HT at 41°C for 1 hour 
In order to maximize the effect of local mild HT on extravascular liposome 
accumulation in tumors, we first compared different thermal doses on 
induction of liposome extravasation and penetration depth in the interstitial 
space. In clinical HT treatments, temperatures of 41 - 43°C are applied. In order 
to avoid permanent vascular damage by HT, we used 41°C for hyperthermic 
tumor tissue temperature. This local mild HT increased the permeability of 
tumor vasculature for extravasation of small liposomes (~85 nm) in time. 
Based on the images prior to injection of the liposomes, vessels were identified 
and a vascular map generated. The quantification analysis applying the 
vascular map revealed time point and extend of liposome extravasation. (Fig. 
1, indicated with arrow heads). Murine BFS-1 sarcoma and LLC carcinoma 
required 20 minutes, murine B16 melanoma and human BLM melanoma 
required 30 minutes exposure at 41°C to initiate liposome extravasation 
(Supplemental Fig. 1). Liposome intensity increased in the EES over time up 
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to 1 hour at 41°C in all tumor models (Supplemental Fig. 1 and Supplemental 
Video S1). As a control, we used normothermia (NT) (no external heating) 
and observed no liposome extravasation during 4-hour period (data not 
shown). As an additional control, we heated the dorsal skin tissues from its 
normal temperature which lies around 30°C in anesthetized mice to core body 
temperature 37°C. Obvious liposome extravasation occurred in murine LLC 
carcinoma, when the window chamber tissue was heated to 37°C for 1 hour 
(Supplemental Fig. 2). 
After identifying the initiation of liposome extravasation, we compared the 
effect of thermal doses 41°C for 30 minutes and 41°C for 1 hour on liposome 
penetration depth and liposome intensity in the EES in all 4 tumor models. 
Longer exposure to mild HT caused more liposome extravasation and 
accumulation in the EES of murine B16 melanoma (30 minutes HT at 41°C + 
1 hour post-HT resting without HT vs. 1 hour HT at 41°C + 30 minutes post-
HT resting without HT) (Supplemental Fig. 3). Quantification demonstrated 
murine B16 melanoma had significantly higher extravascular liposome 
intensity after the thermal dose escalation (Mann-Whitney test, p-value < 
0.05) (Supplemental Fig. 3 b). Yet both thermal doses increased liposome 
extravasation compared to NT. In general, local mild HT at 41°C for 1 hour 
offered sufficient extravascular liposomal accumulation, thus was employed 
for further experiments. 
3.2. Liposome extravasation and penetration depend on tumor type 
Tumor vasculature in all 4 tumor models responded strongly to mild HT at 
41°C for liposome extravasation and subsequent interstitial penetration (Fig. 
1). Tumor vasculature remained functional during and after HT throughout the 
experiments (observed at bright field). Without mild HT, liposomes remained 
within the tumor vasculature, and no liposome extravasation was recorded in 
any of the selected locations up to 2 hours post-injection (Fig. 1 a). Similarly, 
liposome extravasation was negligible in normal vasculature after thermal dose 
of 41°C for 1 hour (Supplemental Fig. 4). Liposome extravasation in murine 
LLC carcinoma was significantly higher compared to murine B16 melanoma, 
murine BFS-1 sarcoma and human BLM melanoma (F-test < 0.001, Kruskal-
Wallis test p-value ≤ 0.05) (Fig. 1 b). Liposome extravasation in murine B16 
melanoma was also significantly higher compared to murine BFS-1 sarcoma 
and human BLM melanoma (F-test < 0.001, Kruskal-Wallis test p-value ≤ 0.05) 
(Fig. 1 b). Among all selected locations throughout the tumors, mild HT at 
41°C for 1 hour induced more than 50% of permeable tumor vascular surface in 
murine B16 melanoma and LLC carcinoma (Fig. 2 a). Although murine BFS-1 
sarcoma and human BLM melanoma tumor vessels responded less to the same 
thermal dose, the permeable tumor vascular surface in murine BFS-1 sarcoma 
and human BLM melanoma still reached more than 25%, which represents a 
more than 50-fold increase compared to human BLM melanoma without HT 
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Supplemental Fig. 1. a) Liposome (red) extravasation through tumor 
vasculature (green) in murine B16 melanoma. Initial liposome extravasation 
occurred at 41°C for 30 minutes, with additional liposome extravasation 
at 41°C for 1 hour. b) Initiation of liposome extravasation in murine LLC 
carcinoma, BFS-1 sarcoma and c) human BLM melanoma during mild HT. 
White arrows indicate permeable tumor vasculature regions. Bar, 200 µm.
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Supplemental Fig. 2. Liposome (red) extravasation through murine LLC 
carcinoma tumor vessels (green) after 37°C for 1 hour. Bar, 200 µm. 
Supplemental Fig. 3. a) Thermal dose compare of 41°C for 30 minutes vs. 41°C 
for 1 hour on liposome (red) extravasation through murine B16 melanoma 
tumor vasculature (green). b) Comparison of extravascular liposome intensity 
and distance from vessels after mild HT at 41°C for 30 minutes (●) and 1 hour 
( ) in murine B16 melanoma (mean ± SEM, n=3). Murine B16 melanoma 
without HT (tissue temperature was at 30°C) ( ) is indicated in b) as controls. 
Bar, 200 µm. *Mann-Whitney test, p-value < 0.05. 
Supplemental Fig. 4. Liposome (red) extravasation through normal vasculature 
(green) before and after mild HT at 41°C for 1 hour. Bar, 200 µm. 
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Fig. 1. a) Liposome (red) extravasation through tumor vasculature (green) with 
or without mild HT for 1 hour. b) Quantification of liposome extravasation 
through tumor vasculature in 4 tumor models under local mild HT at 41°C for 
1 hour. NEF, normalized extravascular fluorescence. Bar, 200 µm. 
(Fig. 2 a). In all HT treated tumors, extravascular liposome intensity increased 
significantly over time in not only the perivascular regions, but also deeper in 
the EES (up to at least 27.5 µm from the vessels), and was most pronounced
in murine B16 melanoma and LLC carcinoma (Fig. 2 b). Over 1 hour at 
41°C, extravascular liposome intensity in murine B16 melanoma and LLC 
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Fig. 2. a) Leaky tumor vessel surface% post-HT or post-NT is demonstrated 
as mean ± SEM (n=3). b) Surface plots of extravascular liposome intensity in 
4 tumor models during HT at 41°C for 1 hour. *Mann-Whitney test, p-value 
≤0.05. Initial liposome intensities at t = 0 min have values greater than 0 is an 
artifact.  
Fig. 3. a) Preservation of liposome (red) extravasation through murine B16 
melanoma tumor vasculature (green) after HT at 41°C for 1 hour. Liposome 
administration was performed in different mice at pre-HT, or 4, 8, 24 hour 
post-HT. Bar, 200 µm. b) Liposome intensity post-injection at 4, 8, 24 hours 
post-HT for a duration of 4 hours in circulation.  Post-HT 4 hours, Post-HT 
8 hours, ● Post-HT 24 hours. *Mann-Whitney test, p-value ≤ 0.05. 
carcinoma increased in all regions up to 27.5 µm away from the vessels, 
while extravascular liposome intensity in murine BFS-1 sarcoma and human 
BLM melanoma was mostly perivascular and dropped more strongly with 
increasing distance from the vasculature, with little liposome intensity at a 
distance further than 10 µm away from the vessels (Fig.  2 b).  
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3.3. Liposome permeable vessels remained for 8 hours 
The duration of the tumor vasculature permeability after local mild HT at 
41°C for 1 hour was studied. It was observed that once tumor vasculature 
responded to mild HT, liposome extravasation continued post-HT. Tumor 
vasculature permeability was preserved for liposome extravasation up to 8 
hours post-HT, but to a lesser extent (Fig. 3). No permeable tumor vessels 
were observed at 24 hours post-HT and liposomes remained confined to the 
tumor vasculature during the subsequent 4 hours of imaging (Fig. 3). Level 
of extravasated liposomes differed significantly at time points 1.5 and 2 hours 
post-injection (Mann-Whitney test, p-value ≤ 0.05) (Fig. 3 b).  
3.4. Heterogeneous tumor vasculature permeability 
The intensity of extravasated liposomes was heterogeneous within the tumor 
and also between different tumor models (Fig. 4 a). Three dimensional 
reconstructions of liposome extravasation in tumor over time demonstrated 
that extravasation started from focal points in the vasculature and was followed 
by a more general extravasation and distribution in these areas (Supplemental 
Video S2). Similar heterogeneity of tumor vasculature permeability was 
also observed in murine LLC carcinoma, BFS-1 sarcoma, and human BLM 
melanoma (data not shown). 
Before HT, tumor endothelial cells appeared as a virtually closed vascular 
lining (Fig. 6 b, left panel Pre-HT). Mild HT at 41°C for 1 hour caused 
discontinuance of tumor endothelial lining, which formed pronounced gaps 
with sizes up to 10 µm between endothelial cells (Fig. 4 b middle and right 
panel, white arrow). Liposomes escaped from circulation through these gaps 
between the endothelial cells (Fig. 4 b, and Supplemental Video S3). We also 
observed similar gaps (10 µm) in murine LLC carcinoma models (data not 
shown). Blood circulation at the region of interest was observed, proving that 
these tumor vessels remained functional after mild HT at 41°C for 1 hour, yet 
allowed extravasation of liposomes. 
3.5. HT increased liposome accumulation in s.c. tumors  
Intratumoral liposome accumulation was visible in mice at 1 hour post-HT 
and increased to a maximum at 4 hours post-HT (Fig. 5). Beyond 4-hour 
post-HT, absolute tumor fluorescence did not further increase, but the TBR 
kept increasing (Fig. 5 b), due to clearance of liposomes from the body in 
combination with prolonged retention in the tumor. Accumulation of 
liposomes in liver and spleen was visualized by in vivo imaging of mice in 
dorsal position (data not shown). Mice without local HT showed no visible 
intratumoral accumulation of liposomes. 
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Fig. 4. a) Post-HT liposome penetration in the interstitial space at five different 
locations of one tumor. b) gaps between endothelial cells (green) post-HT for 
liposome (red) extravasation, in comparison to tumor vessels pre-HT. Bar in 
a), 200 µm. Bar in b), 100 µm.  
Fig. 5. a) In vivo whole body optical imaging of liposome accumulation in s.c. 
human BLM melanoma in mice, images at 0 and 4 hours post-injection with 
and without local HT at 41°C for 1 hour. b) Liposome accumulation tumor-
to-background ratios (TBR) over time with and without local HT (mean ± SD) 
(n=3 for HT group, n=2 for NT group). 
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4. Discussion 
We studied the effect of a clinical thermal dose (41°C for 1 hour) on liposome 
extravasation, and compared this among 4 tumor models. This thermal dose 
is effective to induce permeable tumor vasculature in murine B16 melanoma, 
BFS-1 sarcoma, LLC carcinoma and human BLM melanoma (Fig. 1). Murine 
B16 melanoma and human BLM melanoma can be considered orthotopically 
implanted in our dorsal skin fold window chamber models. The overwhelming 
extravascular accumulation of liposomes implies that local mild HT induced 
sufficient permeable tumor vasculature for liposome extravasation. We did not 
observe liposome accumulation in tumors under NT, nor was extravasation 
observed under HT in non-pathological tissues (Fig. 1 a, and Supplemental 
Fig. 4). These results are indicative for a tumor vasculature specific effect of 
HT. 
We observed deep liposome penetration throughout the tumors, rather than 
perivascular accumulation, by intravital confocal microscopy (Fig. 2 b). Local 
mild HT (39 – 45°C) mediated liposome extravasation has been studied 
previously [21, 27, 22]. Primarily perivascular liposome accumulation was 
observed in human SKOV-3 ovarian carcinoma [21]. Dreher et al. reported 
that increasing molecular weight reduced particle extravasation and resulted 
in perivascular accumulation [28]. We suspect that the differences in thermal 
doses applied may be a cause of variation in the penetration depth. By 
studying these phenomena in several different tumor models, we were able 
to demonstrate that the fraction of heat-responsive tumor vascular surface, 
liposome extravasation depth and intensity in the interstitial space also greatly 
vary among different tumors (Fig. 2). For instance, liposome intensity in the 
EES in murine LLC carcinoma increased in all regions over 1 hour; while in 
murine BFS-1 sarcoma tumor intensity mainly increased in the perivascular 
region (~15 µm away from the vessels) (Fig. 2 b). We speculate that the 
interstitial fluid flow and/or matrix density is significantly different in these 
tumors. Under HT, intratumoral liposome extravasation and accumulation 
patterns are heterogeneous [29]. The permeability of a specific tumor vessel 
does not only depend on perfusion of the vessel, but also on intrinsic profile of 
the endothelial lining and the surrounding microenvironment [30]. This may 
also explain the differences between a permeable part of a tumor vessel and 
a non-permeable part of the same tumor vessel. Liu et al. showed increased 
liposome extravasation in the tumor periphery compared to the tumor center 
in murine 4T1 carcinoma [29]. We further demonstrated that the heterogeneity 
of tumor vasculature permeability can be pinpointed to any vessel regardless 
of its location in the tumor periphery or center (Supplemental Video 2). 
We extensively quantified liposome extravasation and penetration from 
tumor vessels in 3D, which allowed us to demonstrate for the first time, the 
fraction of tumor vasculature that responds to a clinically relevant thermal 
dose, to become permeable for intratumoral liposome accumulation. Tumor 
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vasculature is compact in the microenvironment, especially in the periphery 
of a tumor, where an advanced functional vascular network is often seen and 
the spacing between functional vessels can be limited [31]. In conclusion, we 
observed significant liposome penetration specifically in tumor tissue of up 
to 27.5 µm in the 4 tumor models upon HT, which is in contrast to Kong et 
al. who observed mainly perivascular liposome accumulation in a human 
ovarian carcinoma model. The differences observed amongst the tumor 
models suggest that the liposome extravasation and penetration processes 
are strongly dependent on tumor type and likely depend on structure of the 
interstitial matrix. 
The gaps within the endothelial lining are an indication of the stress induced on 
the tumor vasculature by local mild HT. Due to the use of fluorescently labeled 
liposomes in a recombinant mouse model with constitutive GFP-expressing 
vasculature and high resolution confocal imaging, we were able to capture for 
the first time, endothelial gaps (up to 10 µm) with extravasating liposomes 
induced by mild HT, in tumor vessels that retained their functionality. In 
response to a thermal stress, vasculature within the tumor not only increased 
local blood flow and vasculature dilation, but also increases permeability. 
More crucially, tumor vasculature tends to lose fluid to the interstitial space, 
which profits intratumoral liposome penetration. The thermal dose of 41°C for 
1 hour did not cause any permanent damage (i.e. hemorrhage) to the tumor 
vasculature, but temporarily altered the integrity of the endothelial network. 
It is likely that the heat stress induced loosening of the endothelial cells from 
the basement membrane [32-33].  
A prior study demonstrated that local mild HT at 42°C for 1 hour increased 
the pore cutoff size of tumor microvasculature in human SKOV-3 ovarian 
carcinoma to > 400 nm, while no liposomes of any size (100, 200 or 400 nm 
in diameter) extravasated after 1 hour NT (34°C) [21]. We found that the 
threshold to initiate liposome (~85 nm) extravasation through permeable 
tumor vasculature in various tumor models was 41°C for 30 minutes, and 
that the longer HT exposure leads to increasingly larger volume of tumor 
tissue penetrated by liposomes (Supplemental Fig. 1 and 3). Importantly, 
the permeable tumor vasculature was preserved for at least 8 hours after 
HT, which allows continuous accumulation of long circulating liposomes 
after HT (Fig. 3). Our whole body imaging results indicated that HT treated 
tumors showed a significantly prolonged liposome retention up to 48 hours 
post-HT. Seynhaeve et al. demonstrated tumor vasculature abnormalization 
by tumor necrosis factor (TNF) α causing  tumor vasculature permeability 
and augmented accumulation of liposomal drug (~100 nm) in murine 
B16 melanoma [15]. Comparably, our study illustrated mild HT induced 
hyperpermeability of tumor vasculature in all 4 tumor models, including 
deep penetration in murine B16 melanoma. To apply mild HT for improved 
liposomal drug delivery with success in patients, a better understanding 
346
Li et al. / Journal of Controlled Release, in press
on the mechanism of vascular response is needed. In particular, the matters 
on differences between responding and non-responding tumor vasculature 
require further studies. 
It’s been reported by Gaber et al. that liposome extravasation at NT (34°C for 
1 hour) is negligible, but becomes positive after HT (42 or 45°C for 1 hour) 
[9]. They observed no further liposome extravasation after 24 hours post-HT, 
which is in agreement with the tumor models we experimented in this study 
[9]. We observed remarkable vascular leakage up to 8 hours after mild HT, 
significantly longer than Kong et al. concluded that local mild HT 40 – 42°C was 
able to increase liposome (~100 nm) extravasation in human SKOV-3 ovarian 
carcinoma for 6 hours post-HT [22]. We detected that the window chamber 
tissue temperature was always around 30°C, as the tissue was held away 
from the body and the climate room was set to 30°C meaning that the tumor 
developed under this temperature. With regard to the definition of NT and 
HT, we explored the effect of local mild HT at 37°C, which is the physiological 
human body temperature, but actually represented an elevation of 7°C. To 
our surprise, thermal dose of 37°C for 1 hour also induced significant amount 
of liposome extravasation (Supplemental Fig. 2). Our results imply that the 
difference in temperature between NT under which the tumor developed and 
adapted to (here 30°C) and HT, is responsible for the induction of permeable 
tumor vessels. This finding suggests there is no absolute thermal dose for 
a positive liposome extravasation through permeable tumor vasculature. 
A relative temperature difference that can be reached in a specific tumor 
determines the potential intratumoral liposome accumulation. In relation to 
translational research, we urge that a well-defined temperature measuring 
and controlling system is critical for in vivo studies. Although this is seen in 
our dorsal skin flap window chamber model, further research needs to be 
conducted to proof the hypothesis. 
5. Conclusion 
We identified a minimum thermal dose to initiate liposome extravasation, 
compared tumor vasculature response towards different thermal doses in 
multiple tumor models and defined duration of permeable tumor vasculature. 
For the purpose of increasing anticancer therapeutic efficacy, we have optimized 
the first step in our liposomal chemotherapy approach. The findings from this 
study enable us to first maximize liposomal drug accumulation in tumors, 
after which a subsequent second heat treatment can trigger drug release and 
will deliver high concentrations of bioavailable cytotoxic compounds directly 
to tumors. 
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Supplemental Video S1. 
Liposome extravasation through murine B16 melanoma tumor vasculature 
under mild HT at 41°C for 1 hour. 
Supplemental Video S2. 
Computer modeling of the heterogeneity of liposome extravasation through 
tumor vasculature under HT at 41°C for 1 hour. 
Supplemental Video S3. 
3-D rendering of endothelial gaps induced by mild HT at 41°C for 1 hour. 
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Abstract 
Liposome mediated anticancer drug delivery has the advantage of reducing 
cytotoxicity in healthy tissues. However, undesired slow drug release impedes 
the therapeutic efficacy of clinically applied PEG-liposomal doxorubicin 
(Dox). The aim of this study is to combine stealth thermosensitive liposomes 
(TSL) and local mild hyperthermia (HT) to increase bioavailable Dox levels in 
tumors. Dox was encapsulated in stealth TSL (~80 nm) with optimized PEG 
concentration in the membrane, and compared with lysolipid-based Dox-
LTSL for in vitro stability, release kinetics, and in vivo tumor growth control. 
In vitro cytotoxicity of Dox-TSL against murine BFS-1 sarcoma, human 
BLM melanoma cell lines and Human Umbilical Vein Endothelial Cells 
(HUVEC) under normothermia (37°C) and HT (42°C) was compared with 
non-encapsulated Dox. In vitro Dox uptake in nuclei was imaged in BLM and 
HUVEC. In vivo intravascular Dox release from TSL in BFS-1 tumors under 
local mild HT in dorsal skin flap window chamber models was captured 
by intravital confocal microscopy. Intravascular Dox-TSL release kinetics, 
penetration depth and interstitial Dox density were subjected to quantitative 
image analysis. Systemic Dox-TSL administration in combination with local 
mild HT on subcutaneous tumor growth control was compared to Dox-LTSL 
plus local mild HT. Dox-TSL were stable at 37°C, while released over 95% Dox 
within 1 minute in 90% serum at 42°C. Dox-TSL demonstrated efficient in vivo 
intratumoral Dox release under local mild HT, followed by significant Dox 
uptake by tumor and tumor vascular endothelial cells. Dox-TSL plus mild 
HT showed improved tumor growth control over Dox-LTSL plus mild HT. 
Survival after a single treatment of Dox-TSL plus mild HT was 67%, while 
survival after Dox-LTSL plus mild HT was 22%. This combination of Dox-
TSL and local mild HT offers promising clinical opportunities to improve 
liposomal Dox delivery to solid tumors. 
Keywords: 
Thermosensitive liposomes, hyperthermia, doxorubicin, triggered drug 
release, intravital microscopy, tumor growth control. 
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1.  Introduction 
The current available chemotherapeutic drugs used in conventional or 
combination chemotherapy are associated with substantial side-effects, but 
have often limited benefit to cancer patients [1-2]. Doxorubucin (Dox) is an 
anthracycline antibiotic, and widely used in the treatment of various tumors 
[2]. To reduce these side-effects, liposomal chemotherapy is recommended 
[3-4]. For instance, encapsulating Dox within liposomal nanoparticles 
significantly reduces cardiotoxicity, whilst prolonging the presence of the 
drug in the systemic circulation [5-8]. For these reasons long-circulating or 
stealth PEG-coated Liposomal Doxorubicin (PLD) was approved for clinical 
use (Caelyx ® in Europe and Doxil ® in the USA) [7]. Despite these promising 
aspects, Doxil did not substantially improve efficacy [6, 8]. Preclinical 
evidence suggests that slow and passive drug release from these stealth 
liposomes impedes their therapeutic efficacy [9]. Thermosensitive liposomes 
(TSL) combine the features on high drug loading efficiency and reduced 
toxicity due to liposomal drug encapsulation, with the possibility of triggered 
drug release around a tunable membrane phase transition temperature 
(Tm), typically ~40°C [10-12]. Incorporating Dox into stealth thermosensitive 
liposomes (Dox-TSL) enables a prolonged circulation half-life, and controlled 
localized Dox release from the nanocarrier upon HT [13-15]. However, the 
substantial premature leakage of Dox from lysolipid based TSL (Dox-LTSL) 
at physiological temperature remains an important issue [16-17]. Recently, we 
have reported on an optimized stealth TSL formulation for mild hyperthermia 
(HT) (40-42°C) induced content release [18]. After adopting the optimized 
stealth TSL formulation, we encapsulated Dox into these TSL. 
Mild HT is routinely used in the clinic and is known to strongly improve 
the outcome of chemotherapy or radiotherapy, without significant side effects 
[19-20]. HT can improve the antitumor effect of some chemotherapeutic 
compounds (ie. Dox) by several mechanisms [21]. Increased perfusion, 
vascular permeability and interstitial microconvection cause increased drug 
levels and improved tissue oxygenation [22]. In addition, increased tumor 
cell sensitivity occurs upon mild HT as well as DNA repair inhibition [23-
24]. Although reaching mild hyperthermic temperatures (40-43°C) uniformly 
within a tumor depends on the location of the tumor, and its perfusion, the 
development in technology and equipment nowadays allows for precise 
heating of a defined tissue volume up to 43°C, using external microwave or 
high intensity focused ultrasound [25-26]. 
The combination of Dox-TSL and local HT has the potential to achieve high 
concentrations of bioavailable Dox in heated tumors. Lysolipid-based Dox-
LTSL was invented by Needham’s group, and its temperature sensitivity, 
release mechanisms  were reported [11]. Dox-LTSL is currently under thorough 
study in clinical trials [27, 16]. The approach is to systemically administer 
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long-circulating stealth Dox-LTSL, in combination with local mild HT at the 
tumor to trigger intravascular Dox release from the Dox-LTSL and subsequent 
diffusion of free Dox throughout the HT treated tumor tissue [28]. An essential 
requirement for this approach is a desirable TSL formulation, with minimum 
content leakage at physiological temperature in serum and maximum content 
release at 41-42°C. We have previously reported an optimized TSL formulation 
for content release [18]. In this study, we characterized Dox-TSL for in vitro 
stability and cytotoxicity, in vitro and in vivo Dox release kinetics and cellular 
uptake under mild HT by fluorescence microscopy and confocal microscopy. 
In vivo Dox release and delivery kinetics were quantified and subjected to 
computer modeling. We propose that the optimized Dox-TSL with prolonged 
circulation time at physiological temperature and triggered drug release 
at mild HT further improve the therapeutic efficacy of the combination 
approach. For this purpose, we compared the therapeutic efficacy of Dox-TSL 
with lysolipid based Dox-LTSL for intravascular Dox release upon local mild 
HT, on subcutaneous (s.c.) tumor growth control. 
2. Materials and methods 
2.1. Lipids and chemical reagents 
The phospholipids 1,2-dipalmityol-sn-glycero-3-phosphocholine (DPPC), 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-PEG2000 (DSPE-PEG2000) were provided 
by Lipoid (Ludwigshafen, Germany). Monostearoylphosphatidylcholine 
(MSPC) was purchased from Avanti Polar Lipid Inc. Dox was purchased from 
Pharmachemie. Other chemical reagents were obtained from Sigma Aldrich 
(Netherlands) unless otherwise specified. 
2.2. Liposomes 
TSL at 80 nm in diameter were composed of DPPC/DSPC/DSPE-PEG2000 in a 
molar ratio of 80:15:5. We prepared Dox-LTSL at 120 nm in diameter composed 
of DPPC/MSPC/DSPE-PEG2000 in a molar ratio of 85:10:5 for the comparison 
on the therapeutic efficacy study [29, 17]. Liposomes were prepared by 
lipid film hydration and extrusion method at 60°C (thermobarrel extruder, 
Northern Lipids, Vancouver, Canada) [30, 18]. Filters pore size at 80 – 200 nm 
were used for Dox-TSL, and 100 – 200 nm were used for Dox-LTSL. Size and 
polydispersity index (PDI) were determined by dynamic light scattering using 
a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK). Loading 
of Dox into TSL and LTSL was performed according to a citrate-based pH-
gradient Dox-loading method [31-32], with initial Dox/lipid ratio (mole/mole) 
at 0.15:1 for Dox-TSL and 0.05:1 for Dox-LTSL [17]. Briefly, across membrane 
300 mM citrate pH 4 was inside and HN buffer (150 mM NaCl, 20 mM HEPES) 
pH 7.4 was outside. Mixture of TSL and Dox was incubated at 39°C for 10 
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minutes. Free Dox was removed from suspension by high speed centrifuge 
(maximum radial distance 10.70 cm, 39,000 rpm, at 4°C for 1 hour). Dox-TSL 
and Dox-LTSL were stored in His buffer (150 mM NaCl, 20 mM histidine) pH 
6.5 at -20°C, and used within two weeks. Lipid concentration was measured 
by phosphate assay [33]. Cryo-transmission electron microscopy (Cryo-TEM) 
images of Dox-TSL were captured by a Leo 912 Omega TEM microscope (Carl 
Zeiss NTS GmbH, Oberkochen, Germany) to visualize the encapsulated Dox 
inside of TSL [34-35]. Briefly, a thin liquid film placed on a microperforated 
copper grid was frozen in liquid ethane and prepared for imaging in a cooling 
chamber cooled with liquid nitrogen.  
2.3. Cell lines and culture
Murine BFS-1 sarcoma was obtained from Ludwig-Maximilians University, 
Munich, Germany, human BLM melanoma was obtained from Nijmegen 
University, the Netherlands and Human Umbilical Vein Endothelial Cells 
(HUVEC) were isolated in-house. BFS-1 and BLM were routinely cultured in 
RPMI-1640 medium with 25mM Hepes with 2 mM L-glutamine with 10% fetal 
calf serum (FCS) (Lonza, Belgium), and HUVEC were routinely cultured in 
human fibronectine (Roche) coated flasks (Greiner Bio-One, the Netherlands) 
in DMEM with 4.5g/l glucose with 2 mM L-glutamine, human serum (Lonza, 
Belgium) (20%) and recombinant human basic fibroblast growth factor (Tebu-
Bio) and human endothelial-SFM (InVitrogen). 
2.4. In vitro Dox encapsulation, stability and release kinetics  
Encapsulated Dox was determined after exposure of 20 µl of 5 mM [lipid] 
suspension of Dox-TSL to 180 µl of detergent (2% Triton X-100 in distilled 
H2O) at 45°C for 30 minutes in a thermal-shaker (Eppendorf Thermomixer) at 
1400 rpm to measure maximal Dox fluorescence by spectrofluorometry (Ex. 
482 nm/Em. 594 nm, Ex slit 10 nm/Em slit 5 nm) (Hitachi F-4500 Fluorescence 
Spectrophotometer). After incubation, samples were diluted in 10 mM Tris/
NaCl 0.9% at pH 8.0 at 1:50 (v/v) and measured by spectrofluorometry, as 
positive controls (I∞). Samples in the replacement of detergent to 180 µl of 
pure FCS at 37°C for 1 hour were measured as Dox-TSL leakage (Ileakage). 
Samples in 180 µl of FCS mixed at room temperature were measured as 
negative controls (I0). All samples were adjusted to contain identical amount 
of FCS. Dox encapsulation efficiency was determined as Dox/lipid = [Dox]/
[lipid] [18]. Stability (%) = 100 - (Ileakage - I0)/( I∞ - I0)x100. 
For in vitro temperature-dependent Dox release, 20 µl of 5 mM [lipid] Dox-
TSL suspension in HN buffer 7.4 was added to pre-heated 180 µl of FCS and 
incubated for 5 minutes at desired temperatures (ranging from 37 to 45°C) in 
a thermal-shaker at 300 rpm. After incubation, samples were diluted in 10 mM 
Tris/NaCl 0.9% at pH 8.0 at 1:50 (v/v) and measured by spectrofluorometry. For 
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in vitro time-dependent Dox release, 20 µl of 5 mM [lipid] Dox-TSL suspension 
in HN buffer 7.4 was added to pre-heated 3 ml of FCS and incubated for 1 
hour at 42°C under stirring, and monitored online by spectrofluorometry. 
After 1 hour incubation, 20 µl of 10% Triton X-100 was added to obtain 
maximum Dox release which was used as positive control. Samples mixed 
at room temperature (20°C) were measured as negative controls. Dox-TSL 
encapsulation, stability and release kinetics were compared to Dox-LTSL [15], 
a lysolipid based formulation which is currently in clinical trials. 
2.5. In vitro Dox-TSL cytotoxicity 
BFS-1, BLM and HUVEC were seeded in 96-well flat bottom plates (2,000 
cell/well for BFS-1 and BLM, 6,000 cell/well for HUVEC), and recovered 
overnight. Dox-TSL and Dox were diluted in serum-free medium (at various 
concentrations) and filtrated through 0.45 µm filters before use. After adding 
Dox-TSL and Dox to the cells, the 96-well plates were immediately placed 
in a water bath at HT (42°C) (plates were vacuum sealed to be waterproof) 
or in an incubator at normothermia (NT) (37°C) for 1 hour. The validity of 
the experimental setup was confirmed by comparing cell survival at 72 hours 
post-HT to post-NT. The water bath set at 42.5°C took 10 minutes to heat 
medium to 42°C in the 96-well plates, and an electronic thermometer probe 
was applied to measure medium temperature. After incubation at desired 
temperatures, cells were washed three times with serum-free medium, and 
incubated in fresh medium at 37°C for 72 hours. Cytotoxicity was tested using 
a colorimetric XTT assay for cell viability as described by the manufacturer 
[36]. IC50s (50% cell inhibition) were calculated by interpolation. 
2.6. In vitro cellular Dox uptake
BLM and HUVEC were seeded in rings (4 cm in diameter) on glass pre-coated 
with fibronectin (37°C for 30 minutes) (50,000 cell/ring for BLM, 25,000 cell/
ring for HUVEC), and recovered overnight. HUVEC tended to detach under 
HT conditions, thus low amount of HUVEC was seeded to ease HUVEC 
attachment during the experiments. Hoechst was added to medium without 
phenol red (1:100 in rings) and incubated at 37°C for 30 minutes, to allow 
visualization of nuclei. Medium was then refreshed with Dox-TSL suspension 
(50 µM Dox) in serum -free medium without phenol red. Cells were incubated 
at 37°C (control) or 42°C (HT) for 1 hour (it took 10 minutes to reach medium 
temperature of 42°C). Images (40-fold magnification) of bright field and 
channels for Hoechst (binding to DNA) and Dox were taken pre-HT, every 
10 minutes during HT up to 1 hour under Zeiss microscope 100M (40x oil 
lens) with a Hamamatsu camera. Cells without the addition of Dox-TSL were 
experimented as controls at 42 and 37°C.  
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2.7. Animal models and in vivo tumor models 
C57BL/6 and NMRI nu/nu mice were purchased from Charles River and 
housed at 20-22°C, humidity of 50-60%, and 12 hour light-dark cycles. Sterile 
rodent food and acidified vitamin C-fortified water were given ad libitum. 
Eight-week old mice at weight of 20-25 g were used. Mice with constitutive 
vascular endothelial cell expression of an eNOS-Tag-GFP fusion protein were 
developed by Dr. R. de Crom and R. van Haperen, Department of Cell Biology, 
Erasmus MC, Rotterdam, the Netherlands, bred in-house and used for window 
chamber intravital microscopy studies when appropriate. All animal studies 
were done in accordance to protocols approved by the committee on Animal 
Research of Erasmus MC, Rotterdam, the Netherlands. 
Murine BFS-1 sarcoma and human BLM melanoma cells were routinely cultured 
as described above. Tumor cells (106) were injected subcutaneously in flanks 
of mice, and bulk tumors of 1 cm in diameter were used for transplantation. 
A small viable tumor piece (~1 mm3) of murine BFS-1 sarcoma was removed 
from the bulk tumor and transplanted in the fascia of a dorsal skin flap placed 
in a window chamber in mice [18]. For in vivo efficacy study, a tumor piece (~3 
mm3) of human BLM melanoma was transplanted subcutaneously in the hind 
leg of NMRI nu/nu mice. After tumor transplantation, mice carrying window 
chambers were housed individually at 30°C and 60% humidity. Mice were 
used for experiments, when tumors reached ~5 mm in diameter in dorsal skin 
flap window chamber models and s.c. models.
2.8. In vivo Dox release 
  
In vivo Dox release kinetics was studied by intravital fluorescence microscopy. 
Mice were anesthetized with isofluorane (Nicholas Piramal, London, UK) and 
placed on a thermal mattress at 37°C during experiments. An external circular 
resistive heating coil was attached to the glass at the back side of the window 
chamber to provide homogenous local HT [18]. Thermocouples (point-
welded thin manganese and constantan wires from Thessco®, Amsterdam) 
were imbedded in window chambers to monitor tissue temperature online. 
Dox-TSL (7 mg/kg) was injected intravenously through the tail vein. Regions 
of interest were selected by confocal microscopy (Zeiss LSM 510 META). 
Background images were captured before liposome administration. Amplifier 
offsets for both GFP and Dox were adjusted to intensity 0 when the lasers were 
off for initial image calibration. Initial images were taken, and then heating 
was started within 20 minutes post-administration. Window chamber tissues 
were heated up to 42°C in ~10 minutes and remained for 1 hour, followed by 
resting without HT (temperature decreased down to 30°C in ~15 minutes). 
Dox release was monitored online by a Helium-Neon laser (543 nm), and 
GFP-expressing endothelial cells were visualized by an argon laser (488 nm). 
Fluorescent channels (GFP: BP 505-550, Dox: LP 585, Plan-Neofluar 10x/0.3 
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lens) were recorded in 40 µm thin single images and 120 µm thick Z-stack 
before and after HT. Intermittent images were taken every 8 seconds during 
heating, HT at 42°C. Images with higher magnifications (Plan-Neofluar 20x/0.5 
lens, scan zoom 2.0) were taken at the end of the experiments to capture Dox 
uptake in nuclei. Images of 512x512 pixels were analyzed with LSM image 
software (Zeiss, Germany). Dox intensity was quantified as fluorescence 
intensity (AU) (area unit) by Image J (Wayne Rasband, National Institutes of 
Health, USA). 
2.9. Quantitative image analysis 
In vivo Dox release upon local mild HT was quantified by image processing 
methods in software Matlab and MeVisLab. Motion compensation was 
performed by geometrical transformation between images in each time series. 
Intravascular regions were identified by GFP-tag endothelial lining. Vessel 
distance maps were then generated by Euclidean distance transfer [37], and 
average Dox fluorescence intensity calculated depending on distance to 
closest vessel, up to 27.5 µm [38]. Dox penetration during HT was visualized 
by surface plots.   
2.10. Therapeutic efficacy and tumor growth control 
NMRI nu/nu mice were transplanted with s.c. human BLM melanoma in 
their right hind legs. Upon reaching tumor size of 5 mm in diameter, mice 
were anesthetized, and the right tumor bearing hind legs were covered in 
aquasonic ultrasound gel (Parker Laboratories, Inc.) to ensure efficient 
heat transfer to the tumor surface. Surrounding tissues and muscles were 
protected by a syringe. The hind legs were maintained inside of the syringes 
and fixed onto a rack to ensure a steady position in a water bath during the 
HT treatment. When tumor temperature reached 42°C, Dox-TSL and Dox-
LTSL in PBS suspension were administered at 3 mg/kg through a tail vein. 
The tumor temperature was maintained at 42°C for 1 hour. Mice with Dox-
TSL and Dox-LTSL administration under NT, and with PBS administration 
under HT or NT were used as control groups.  Mice were then released back 
to their cages. Tumor size was measured on the day of experiments, and every 
other day after experiments. When tumor size reached 2 cm3 (Height x Width 
x Depth x 0.4), mice were euthanized, otherwise mice were euthanized on day 
26 post-treatment. Tumor size related euthanization was used as measure for 
survival. 
2.11. Statistics 
All in vitro data are represented as mean ± standard error of the mean (SEM) 
of experiments in triplicates, and analyzed by paired Mann-Whitney test 
(p-value ≤ 0.05). In vivo results are analyzed by Kruskal Wallis for multiple 
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groups. 
3. Results 
3.1. In vitro characterization of liposomes 
In vitro Dox-TSL size, size distribution, stability, temperature-dependent 
and time-dependent Dox release kinetics were determined (Table 1). Size 
and homogeneity of the TSL population were confirmed by Cryo-TEM (Fig. 
1A) [35]. Dox was present in the liposome interior in a crystallized form as 
demonstrated by the electron dense fibrous appearance inside TSL. These Dox-
TSL were stable during storage at -20°C for up to 5 weeks with Dox retention 
in TSL > 80% (data not shown). In the temperature-dependent release assay, 
Dox-TSL released their content with increasing temperature, starting at 39°C. 
Over 80% of Dox was released at the optimal temperature for this formulation 
at 42°C in 5 minutes in the presence of 90% FCS (Fig. 1B) [18]. By contrast, 
LTSL already released significant quantity of their Dox in 5 minutes at 37°C in 
90% of serum and reached maximal release temperature at 40-41°C.  
Table. 1. Liposome characterization.
*Nonparametric Mann-Whitney test, p value ≤ 0.05. Data are represented as 
mean ± standard error of the mean (SEM), N=3. 
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Fig. 1. Cryo-TEM image of Dox-TSL (A). Bar, 200 nm. Temperature-dependent 
Dox release from TSL and LTSL during 5 minutes incubation in serum at 
different temperatures (B). Dox-TSL in 50% FCS (□), Dox-TSL in 90% FCS ( ), 
Dox-LTSL in 50% FCS ( ), Dox-LTSL in 90% FCS (●). Time-dependent Dox 
release from Dox-TSL and Dox-LTSL during 1 hour incubation at 37°C and 
42°C in 99% FCS (C). Dox-TSL at 37°C (□), Dox-TSL at 42°C ( ), Dox-LTSL at 
37°C ( ), Dox-LTSL at 42°C (●). N=3.  
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At the optimal Dox-TSL release temperature 42°C, we followed release rate 
in time. Dox-TSL released virtually all its Dox in 5 minutes in the presence 
of 99.3% FCS (Fig. 1C). In vitro stability characterization revealed Dox-TSL to 
be more stable at 37°C in the presence of serum than LTSL, which released 
significantly more Dox under these physiological conditions (Table 1).  Yet 
Dox-TSL displayed fast Dox release at mild HT. 
3.2. In vitro cytotoxicity 
The cytotoxicity of Dox-TSL was tested under short-term (1 hour) mild HT 
(42°C) and NT (37°C) conditions toward murine BFS-1 sarcoma, human BLM 
melanoma cell lines, and HUVEC. The cytotoxicity of Dox-TSL under HT was 
equivalent to free Dox under HT in both murine BFS-1 sarcoma and human 
BLM melanoma cell lines (Table 2, Fig. 2B,C). Dox-TSL showed a 60-fold 
and 80-fold decrease in IC50 upon HT compared to NT against murine BFS-1 
sarcoma and human BLM melanoma cell lines (Table 2). Free Dox under HT 
caused a 4-fold reduction on IC50 compared to NT in both tumor cell lines 
(Table 2). In view of possible delivery of Dox to tumor vascular endothelial 
cells we also investigated in vitro Dox delivery to proliferating endothelial 
cells (HUVEC). For HUVEC, HT also caused a decrease in the IC50 of Dox-TSL 
(10-fold reduction compared to NT) (Table 2). However, HUVEC, in contrast to 
both BLM and BFS-1 tumor cell lines displayed similar Dox chemosensitivity 
regardless of HT or NT (Fig. 2C and Table 2). 
Table. 2. IC50 (µM) of Dox-TSL in comparison to Dox. 
Data are represented as mean ± SEM. N=3.
Fig. 2. In vitro cytotoxicity of Dox-TSL against murine BFS-1 sarcoma (A), 
human BLM melanoma (B) cell lines and HUVEC (C).  Dox-TSL at 37°C (□), 
Dox-TSL at 42°C ( ), Dox at 37°C ( ), and Dox at 42°C (●).Data are represented 
as mean ± SEM. N=3.  
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3.3. In vitro Dox uptake in nuclei 
Upon exposure of human BLM melanoma cells and HUVEC to Dox-TSL under 
HT (42°C) and NT (37°C) for 1 hour, cellular uptake of Dox was monitored 
online. Nuclear co-localization of Dox and Hoechst was observed (Fig. 3). 
Under HT, nuclear uptake of Dox was visualized when BLM melanoma 
cells were maintained at 42°C for 10 minutes, and Dox intensity in nuclei 
continuously increased. In 30 minutes under HT, almost all Dox released from 
Dox-TSL in the medium had been taken up by nuclei. Nuclear uptake of Dox 
from Dox-TSL was much less and slower under NT (Fig. 3). By the end of 1 
hour NT, nuclear update of Dox from Dox-TSL was less than that observed at 
30 minutes HT in both human BLM melanoma cells and HUVEC. 
Fig. 3. In vitro cellular Dox uptake by human BLM melanoma cell line and 
HUVEC upon incubation with Dox-TSL at HT and NT. Bar, 50 µm. 
462
Li et al. / Journal of Controlled Release, submitted
3.4. In vivo Dox release from Dox-TSL under local mild HT 
In vivo Dox release from TSL was observed by intravital fluorescence microscopy 
on dorsal skin flap window chamber models in mice implanted with murine 
BFS-1 sarcoma. In agreement with in vitro stability data (Fig. 1) Dox-TSL were 
stable at 37°C in circulation with minimal Dox fluorescence detected (Fig. 4A). 
Dox-TSL started to slowly release Dox intravascularly, when the temperature 
in the tumor reached 40°C (Fig. 4A). Massive Dox release occurred when the
Fig. 4. In vivo Dox release from Dox-TSL in murine BFS-1 sarcoma (A), and 
subsequent cellular uptake by murine BFS-1 sarcoma cells and endothelial 
cells (B). Images are presented as merged GFP endothelial cells (green) and 
Dox (red) fluorescence. Bar in A, 200 µm. Bar in B, 50 µm. Quantitative Dox 
intensity and penetration depth during mild HT, tumor tissue temperature 
reached 42°C by 20 minutes (C). 
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temperature was reaching 42°C (Fig. 4A). It took 2 minutes to increase from 40 
to 42°C. Dox from circulating Dox-TSL was continuously delivered to tumor 
tissue upon Dox-TSL passage through the heated tumor vasculature. Released 
Dox rapidly penetrated tumor tissue and was internalized quickly by tumor 
cells and vascular endothelial cells accumulating at high concentrations in their 
nuclei (Fig. 4B). Upon HT, a boost of intravascular Dox release caused a major 
initial homogeneous Dox delivery throughout the tumor tissue. Dox quickly 
diffused and penetrated further into the interstitial space up to at least 50 µm 
away from the tumor vasculature (Fig. 4C and Supplemental Video 1). After 
30 minutes HT, intravascular Dox intensity started to decrease, as circulating 
Dox-TSL had emptied their contents and Dox concentrated in nuclei (Fig. 4C). 
Moreover, the stable Dox intensity also indicates a continuous Dox delivery to 
extravascular extracellular space (EES) during HT, as a supply for subsequent 
cellular uptake. The Dox concentration in cellular nuclei continued to increase 
during HT (Supplemental Video 1). In vivo Dox release demonstrated efficient 
local mild HT controlled intravascular Dox release from Dox-TSL and rapid 
intracellular accumulation.
Correlations of time, Dox concentration and penetration depth were 
demonstrated in a mathematical model (Fig. 4C). Homogeneous Dox 
intensity increased to maximal of over 8-fold compare to initial Dox intensity 
(200 AU) during heating period with tissue temperature of 42°C (1400 AU). 
Steady increase in fluorescence up to HT at 42°C for 30 minutes, after which 
a decrease was observed. This indicated liposomes were emptied and Dox 
intensity became heterogeneous throughout the tumor tissue as soon as 
cellular uptake of Dox became dominant and remained stable afterwards 
(Supplemental Video 1). 
3.5. Tumor growth control 
Treatments of systemic Dox-TSL and Dox-LTSL in combination with local 
mild HT at tumors were compared for tumor growth control in human 
BLM melanoma xenografts. Dox-TSL showed overall better tumor growth 
control than Dox-LTSL over a time course of 26 days after a single treatment 
of intravascularly triggered Dox release by local mild HT (Fig. 5A,B). Mice 
after the treatment of Dox-TSL and mild HT had tumor growth delay of ~16 
days, while mice after the treatment of Dox-LTSL and mild HT had tumor 
growth delay of 8 days. By Day 26, 6 out of 9 mice survived with end tumor 
size <11x15x10 mm3 after treatment of Dox-TSL and local mild HT; while 
only 2 out of 9 mice survived with end tumor size of ~13x16x12 mm3 after 
treatment of Dox-LTSL and local mild HT. In sham group, all of 9 mice had 
to be euthanized because of large tumor size. Intravascular release of Dox 
from Dox-TSL showed improved survival of mice bearing s.c. human BLM 
melanoma up to 26 days after a single treatment (Fig. 5C).
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Fig. 5. Tumor growth control of Dox-TSL and Dox-LTSL (A, B). Dox-TSL with 
HT ( ), Dox-LTSL with HT ( ), PBS with NT ( ). Data are represented as 
mean ± SEM. N=4. Compare of survival after a single treatment (C). Dox-TSL 
with HT (–), Dox-LTSL with HT (- -), PBS with NT (∙∙∙∙). N=9. 
4. Discussion 
Dox-LTSL have been studied in combination with local HT at tumor sites 
[11] to induce intravascular drug release-mediated control of tumor growth 
and are currently in clinical trials [27, 16, 28]. Lysolipid-based Dox-LTSL are 
known to release significant quantities of Dox at physiological temperatures 
in serum and thus have a fast plasma clearance upon administration [32, 16, 
39-40]. Inspired by these prior promising results, we aimed to further improve 
TSL-mediated drug delivery by establishing a more stable formulation. We 
omitted the lysolipid and made use of an optimal DSPE-PEG2000 density to 
prolong drug retention at physiological temperature in circulation with peak 
rate at 42°C [18]. These Dox-TSL were significantly smaller (80 nm) than LTSL 
(120 nm) [29, 17], to further promote rapid release at their Tm [41]. 
Dox can relatively rapidly pass cellular membranes followed by strong 
binding to DNA in cellular nuclei. Because of the increased perfusion, vascular 
permeability and microconvection in the EES induced by HT, after release, 
Dox distributed homogeneously into tumor tissue at distances up to 50 µm 
away from tumor feeding blood vessels (Fig. 4). In addition, Dox delivery 
continued to increase during the course of the HT treatment, due to new drug-
filled Dox-TSL being available in circulating and arriving in the heated tumor 
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tissue. Due to the continuous supply of drug-loaded TSL, Dox delivered by 
TSL will penetrate deeper into EES than administration of free Dox, which is 
rapidly cleared from circulation [7]. Importantly, we observed nuclear Dox 
uptake in vivo in tumor cells as well as in tumor vascular endothelial cells (Fig. 
4B). Thus, intratumoral Dox release from Dox-TSL causes a dual targeting of 
both intratumoral endothelial cells and adjacent tumor cells. We were able to 
demonstrate that in vitro exposure of HUVEC to Dox in free form and Dox-TSL 
in combination with mild HT causes significant intracellular Dox delivery and 
concomitant cytotoxicity, at levels similar to those observed in tumor cells. 
For local mild HT induced intravascular drug release approach, lysolipid-free 
Dox-TSL with a prolonged stability at physiological temperature, are expected 
to provide significantly higher dose of bioavailable Dox at tumor sites. Dox-
TSL showed a prolonged tumor growth control and improved survival by 
4-fold over Dox-LTSL (78% v.s. 22%). Our cytotoxicity results indicated that 
murine BFS-1 sarcoma and human BLM melanoma cell lines had a lower IC50 
than HUVEC upon combining HT and Dox, in contrast to incubations with 
Dox, but without HT. This finding suggests cancer cells are more prone to 
thermal stress than normal cells, which leads to cell sensitization towards a 
chemotherapeutic compound [42-44]. HT is known to sensitize tumor cells 
through enhancing drug uptake, initiating cellular stress responses [45] and 
by inhibiting DNA repair [24]. Apparently normal endothelial cells do not 
show such sensitization to Dox treatment. Future studies will be focused on 
the exact contribution of cytotoxicity done to both cell types to the overall anti-
tumor activity, for instance by making use of cell-specific targeted triggered 
drug delivery approaches [46-48]. 
Intravascular drug release leads to a concentration gradient from the vessels 
into the tissue, which means perivascular regions normally receive a higher 
dose of chemotherapy than hypoxic and necrotic regions. Smart application 
of mild HT with thermosensitive nanocarriers for chemotherapeutic drug 
delivery has the potency to strongly improve drug levels also in tissues further 
away from functional vessels due to HT-mediated enhancement of tumor 
perfusion, vascular permeability and interstitial fluid flow. Combining these 
benefits of HT with optimal thermosensitive nanocarriers that demonstrate 
high levels of nanoparticle extravasation [49-50] and penetration into tumor 
tissues [50], HT triggered drug release bears the potential to significantly 
improve tumor drug delivery. 
5. Conclusion 
Our study provides a detailed in vitro and in vivo study toward an optimized 
nano-sized Dox-TSL formulation, in which several critical aspects for stability 
and triggered drug delivery were combined. This resulted in Dox-TSL 
with high drug loading efficiency, stability at physiological temperature in 
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circulation, and fast drug release potential under local mild HT. These Dox-
TSL showed improved tumor growth control and overall survival compared 
to Dox-LTSL through an intravascular drug release upon local mild HT. The 
combination of the optimized Dox-TSL and local mild HT resulting in drug 
delivery to both tumor and tumor vascular endothelial cells may thus lead to 
clinically more efficacious advanced drug delivery systems.  
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Nanocarriers 
Nanoparticles can deliver a plethora of compounds such as chemotherapeutic 
drugs, contrast agents, genetic materials for both clinical diagnostics and 
treatment [1-3]. Multidisciplinary studies include the fields of material 
engineering, chemistry, genetics, proteomics, etc. [4-6]. In view of nanoparticle-
mediated delivery of anticancer drugs, numerous new developments are 
being reported, e.g. on the incorporation of doxorubicin (Dox) into various 
nanoparticles for cancer treatment [7-11]. In this thesis, Dox is employed as 
the chemotherapeutic agent for the treatment of solid tumors. Liposomes of 
~100 nm in diameter are chosen as nanoparticles for drug encapsulation and 
triggered release. An external stimulus of mild HT is applied to manipulate 
tumor microenvironment for improved liposomal drug delivery and triggered 
drug release from the liposomal nanocarrier. 
DSPE-PEG2000 in liposomes 
Incorporation of DSPE-PEG2000 in the liposome membrane affects membrane 
integrity and permeability, however the presence of PEG at the liposomal surface 
through a phospholipid bilayer anchor, is necessary for stealth liposomes with 
favourable pharmacokinetics [12-17]. More, DSPE-PEG2000 prevents liposome 
aggregation in plasma [18]. In this thesis, classic temperature sensitive 
phospholipids 1,2-dipalmityol-sn-glycero-3-phosphocholine (DPPC) and 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) are adopted to guarantee an 
active content release of thermosensitive liposomes (TSL) upon mild HT [19]. 
The fine-tuning of DSPE-PEG2000 concentration for TSL generates essential 
features for both stability and release. TSL with optimized 5 mol% of DSPE-
PEG2000 showed significant higher content retention in serum at physiological 
temperature than TSL with higher DSPE-PEG2000 concentrations, whereas 
content release of TSL with DSPE-PEG2000 densities lower than 5 mol% were 
only suboptimal. In Chapter 2, an optimal DSPE-PEG2000 concentration was 
defined for the first time, for the use of TSL in combination with mild HT 
for triggered content release [20]. DSPE-PEG2000 grafted on membrane surface 
causes steric repulsion between opposing polymers [21]. DSPE-PEG2000 can 
form interdigitated mushroom, mushroom or brush regimes, depending on 
the density of grafting sites and DSPE-PEG2000 polymer size [22]. DSPE-PEG2000 
from 1 to 4 mol% increases mushroom regime, while DSPE-PEG2000 from 4 
to 5 mol% drives mushroom-to-brush transition. Thus, the mix of regimes 
present during Tm in this optimized formulation is expected to ease content 
release. When DSPE-PEG2000 further increases from 5 to 10 mol%, rigid brush 
regime grafted on the inner surface of lipid membrane occupies space of the 
aqueous core, reducing content encapsulation in our TSL. A dramatic decrease 
in content encapsulation was also observed in another TSL formulation 
(involving novel lipid 1,2-dipalmitoyl-sn-glycoero-3-phosphoglyceroglycerol) 
with 10 mol% DSPE-PEG2000 by Hossann et al. [23-24]. In addition, Kenworthy 
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et al. found no further increase of liposome circulation time, when PEG-lipid 
concentration was more than 10 mol% [21]. They and others stated that higher 
concentrations of DSPE-PEG2000 or DSPE-PEG5000 would promote the formation 
of micelles and destabilization of liposomes [17]. It is likely that the micelle 
forming tendency of PEG-DSPE also could explain the increasing instability 
of our TSL formulation at PEG density of 6 mol% and higher. On the other 
hand, the heterogeneous DSPE-PEG2000 regimes around 5 mol% seems to 
stabilize the grain boundaries in DPPC/DSPC bilayers optimally, enhancing 
content retention at physiological temperature and release upon reaching Tm. 
In comparison, lysolipids are thought to also localize at the grain boundaries 
and cause porous defects upon reaching Tm, yet lysolipid presence also causes 
significant leakage of contents at physiological temperature. In an attempt to 
further stabilize lysolipid-based TSL (LTSL) the DSPE-PEG2000 concentration 
was also increased from previous 3.8 mol% to recent 5.2 mol% [25-26]. The 
combination of lysolipids and DSPE-PEG2000 can be replaced by single-chain 
pegylated Brij surfactants, and these Brij-TSL display a similar stability and 
release kinetics to lysolipid-based TSL [27-28]. The selection of Brij surfactants 
is based on their unique structure, which resembles single-chain lysolipids 
and DSPE-PEG2000. Therefore, the loss of Dox from Dox-LTSL at 37°C was also 
resembled in Dox-Brij-TSL for the same reason. Lysolipids and Brij have the 
tendency to dissociate from the lipid membrane, causing Dox leakage [29-
30, 27]. Although Brij surfactants are interesting alternatives to lysolipids and 
DSPE-PEG2000, the pK of neither Dox-LTSL nor Dox-Brij-TSL is desirable for 
intravascular drug release, for which high concentration of liposomal drugs 
in circulation is required. In Chapter 4, in vitro studies present that Dox-TSL 
(DPPC/DSPC/DSPE-PEG2000 in molar ratio of 85:10:5) have significantly more 
Dox retention at 37°C in serum than Dox-LTSL (DPPC/MSPC/DSPE-PEG2000 
in molar ratio of 85:10:5). An in vivo therapeutic efficacy study also presents 
that mice treated with Dox-TSL have longer tumor suppression and improved 
survival compared to Dox-LTSL, when applied in combination with local 
mild HT for intravascular drug release (Chapter 4). These results are likely to 
be explained by improved drug retention in circulation. However, pK study 
is required to prove the speculation. A balance between release rate at mild 
HT and stability at physiological temperature may better serve intravascular 
drug release. A Dox-TSL formulation with slower Dox release rate at mild 
HT of 42°C and high Dox retention at 37°C is designed for interstitial drug 
release in a two-step mild HT approach (Chapter 5). The optimal DSPE-
PEG2000 concentration also benefits other non-temperature sensitive liposome 
formulations on drug loading efficiency, pK, and shelf-life. 
TSL formulations for intravascular and interstitial drug release 
Two TSL formulations are designed in this thesis, DPPC/DSPC/DSPE-PEG2000 
in molar ratios of 80:15:5 and 55:40:5 (Chapter 2, 4 and 5). These fast and slow 
drug release formulations differ in stability and release kinetics at mild HT, 
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in order to suit treatment planning for intravascular and interstitial drug 
delivery [31]. Local mild HT at tumors to trigger drug release from circulating 
TSL is defined as intravascular release [25-26]. In this setting, intratumoral 
drug uptake relies on diffusion of drug after release, while redistribution 
of drug through circulation leads to systemic toxicity. In case of Dox-LTSL, 
inefficient Dox retention at 37°C in circulation also contributes to systemic 
toxicity. Local mild HT at tumors to trigger drug release from TSL in the 
extravascular extracellular space (EES) is defined as interstitial release. 
Intratumoral drug concentration highly depends on TSL extravasation 
and penetration in the interstitial space. The first, fast releasing, TSL (Dox-
fTSL) formulation features a Tm at 43°C with rapid drug release at 42°C, 
which is desirable for intravascular content release from TSL upon mild HT 
(Chapter 4). However, different from the lysolipid-based TSL, which have a 
fast drug plasma clearance upon administration because of substantial Dox 
leakage at physiological temperature, Dox-fTSL improve content retention 
at physiological temperature (Chapter 4) [24, 32, 30, 33]. The second, slow 
releasing, TSL formulation (Dox-sTSL) with increased DSPC incorporation 
features a Tm at 45°C, resulting in significantly lowered content leakage of 
Dox-fTSL at 37°C, while still actively releasing their contents at 42°C, yet 
over a prolonged period of up to one hour (Chapter 5). Dox-sTSL is preferred 
for extravascular content release, which excessively relies on intratumoral 
liposome accumulation through liposome extravasation and penetration 
across tumor vasculature (Chapter 5). 
Intravascular drug release approach 
For intravascular drug release, Dox-fTSL is administered systemically 
followed by mild HT locally applied at tumors to trigger Dox release (Chapter 
4). In vitro Dox-fTSL releases over 90% of its Dox within 5 minutes at 42°C, 
and in vivo circulating Dox-fTSL releases all Dox within 30 minutes at 42°C as 
evidenced by intravital confocal microscopy (Chapter 4). Thus, for the purpose 
of triggering Dox release, a thermal dose of 42°C for 30 minutes would be 
sufficient. However, local mild HT at tumors also increases the blood flow and 
interstitial fluid flow, which facilitates the intratumoral delivery of Dox-fTSL 
(Chapter 3) [34]. In addition these processes after Dox release from Dox-fTSL, 
favor the penetration of Dox throughout the tumor, which was demonstrated 
to increase up to 30 minutes during 1 hour mild HT treatment (Chapter 4). 
On the one hand, increased blood flow brings Dox-fTSL into heated tumors 
for drug release. On the other hand, increased blood flow may counteract 
the intratumoral drug accumulation by circulating drugs to redistribute in 
the rest of the body. It only takes about 20 seconds if not less for Dox-fTSL 
and Dox-LTSL in circulation to pass through heated tumors [35]. Therefore, 
ultra-fast drug release from TSL upon mild HT is crucial to meet the needs 
of intratumoral-intravascular drug release. In terms of encapsulated drugs, 
chemotherapeutic compounds with high cellular binding affinity are preferred 
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to ensure sufficient intratumoral drug uptake, minimizing drug washout. In 
Chapter 4, mild HT plus Dox-LTSL suppresses tumor growth of s.c. human 
BLM melanoma in mice for 8 days, while mild HT plus Dox-fTSL doubles 
tumor growth suppression to 16 days. More, mild HT plus Dox-fTSL triples 
survival of mice bearing s.c. human BLM melanoma by mild HT plus Dox-
LTSL. Mild HT at 42°C also sensitizes in vitro tumor cell lines (murine BFS-1 
sarcoma and human BLM melanoma) towards Dox-TSL, and speeds up the 
nuclear uptake of Dox in human BLM melanoma cell line and human umbilical 
vein endothelial cells (HUVEC) (Chapter 4). Heat stress causes cellular protein 
denaturation. Moreover, nuclear compartment is most sensitive for protein 
aggregation, which may contribute to cell death upon heat stress [36-39]. Some 
studies imply that chemotherapy combination with mild HT shows better cell 
killing. Comparing Dox-TSL and Dox-LTSL, the higher intratumoral chemo-
dose leads to greater inhibition of cell proliferation, tumor suppression and 
better survival. In general, mild HT for 1 hour offers more advantages than 
mild HT for 30 minutes. Apart from duration, hyperthermic temperatures are 
just as important. Mild HT at 39°C can generally induce content release of 
most TSL with Tm around mild HT. Nevertheless, in many cases, TSL content 
release at 39°C is considered premature leakage, which shall be prevented if 
possible. Dox-fTSL has lesser leakage than Dox-LTSL at 39°C and significantly 
more Dox retention at 37°C, yet comparable release at 41-42°C (Chapter 4) 
[26]. Mild HT at 41-42°C is feasible in clinical application, however, it is highly 
dependent on tumor size, location and perfusion. Mild HT above 43°C can 
cause irreversible vascular damage, and is also difficult to reach in the clinic 
because of acute local discomfort on patients’ disease sites. Therefore, TSL 
design with an aim for rapid release at mild HT of 41-42°C in combination 
with high stability at physiological temperature has optimal potential for 
successful clinical application.  
Interstitial drug release approach 
Interstitial drug release relies on intratumoral liposomal drug accumulation. 
Mild HT at tumors induces hyperpermeable tumor vasculature for liposomal 
drug extravasation and penetration into the EES (Chapter 3) [40-41]. The 
minimal thermal dose of 41°C for 30 minutes is sufficient to alter tumor 
vasculature permeability in four most common murine and xenograft tumor 
models. Mild HT of 41°C for 1 hour temporarily elevates tumor vasculature 
permeability for 8 hours post-HT, allowing liposomal drugs to escape from 
circulation and penetrate at least 27.5 µm into the interstitial space (Chapter 3). 
The observed duration of permeable tumor vasculature is significantly longer 
than that observed by Kong et al., who also mainly observed perivascular 
liposome accumulation and no deep tissue penetration [40-41]. Upon mild 
HT, intratumoral liposomal drug accumulation is heterogeneous, because of 
heterogeneous tumor vasculature permeability and perfusion. The temporarily 
elevated blood flow, insterstitial fluid flow and pressure changes during mild 
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HT are driving forces for liposomal drug deep penetration in the EES. The 
complexity of the EES depends on tumor type, size and structure of the specific 
interstitial matrix. Mild HT can have greater influence on the interstitial 
fluid flow, when the matrix structure is scattered. The level of interstitial 
liposomal drug accumulation is also determined by the size of liposomes. 
Chauhan et al. reported that decreasing interstitial fluid flow hindered the 
delivery of nanoparticles at 125 nm in diameter, however improved the 
delivery of nanoparticles at 12 nm in diameter [42]. This approach of tumor 
vasculature normalization by blocking vascular endothelial growth factor 
(VEGF) receptor-2, reduced pore size on vessel walls, increased steric and 
hydrodynamic hindrances, therefore limits liposome size for intratumoral 
accumulation. In contrast, we observed that mild HT enlarges the gaps 
between endothelial cells up to 10 µm to maximize extravascular localization 
of liposomes. This approach of tumor vasculature abnormalization is 
applicable to a broad spectrum of nanoparticles. For interstitial drug release, 
intratumoral accumulation of liposomal drugs rather than the actual drug 
release determines the therapeutic efficacy (Chapter 5). Two-step mild HT 
approach delivers drugs into tumors by firstly inducing hyperpermeable tumor 
vasculature for liposomal drug extravasation and penetration into the EES 
and secondly releasing drugs from TSL to induce their bioavailability. Long-
circulating slow content releasing TSL are most adequate for two-step mild HT 
approach. Extravascularly accumulated Dox-sTSL slowly releases Dox upon 
mild HT at 42°C for 1 hour, comparably extravascular, non thermosensitive 
PLD (Doxil) also passively releases Dox over time through degradation or 
tumor cell internalization [43]. Tumor growth control and survival indicate 
that PLD in combination with two-step approach is as effective as Dox-sTSL 
in combination with two-step approach. The long-circulating nature of PLD 
and the first step of mild HT that induced hyperpermeable tumor vasculature 
both enable a maximal intratumoral PLD accumulation. These results confirm 
the importance of such an intratumoral liposomal drug accumulation process. 
As a matter of fact, mild HT to induce permeable tumor vasculature suits 
most nanocarriers if not all, for intratumoral drug delivery. 
Intravascular vs. interstitial drug release 
Comparing intravascular and interstitial drug release upon mild HT, TSL 
formulations with stable drug retention at physiological temperature are 
required for both approaches. For intravascular drug release, rapid drug 
release and precise heating of tumor volume are equally important for 
therapeutic efficacy [26]. However, for interstitial drug release, neither rapid 
drug release nor precise heating of tumor volume is essential for therapeutic 
efficacy (Chapter 5). This is because tumor vasculature responds significantly 
and becomes permeable upon mild HT, while normal vasculature remains 
intact (Chapter 3). This innate feature of tumor vasculature allows combination 
of TSL with regional mild HT when precise heating of tumor volume is not 
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feasible. After the first step of mild HT, systemic liposomal drugs of all kinds 
have the opportunity to gradually extravasate through permeable tumor 
vasculature and localize in tumors. Subsequent drug release and uptake by 
cells are much less time-restricted than with intravascular drug release. When 
mild HT is applied as the first step of mild HT, interstitial drug release is 
expected to be beneficial for advanced stages of cancer with multiple metastatic 
sites. Upon accumulation of liposomal drugs at metastatic sites, drug delivery 
depends on slow passive release or active triggered release. In case of mild 
HT triggered drug release from TSL, imaging guided drug release is feasible 
for clinical practice. 
Heat cycling 
Heat cycling is to alternate heat on and off moments. Considering the current 
technologies on mild HT, microwave applicators can provide continuous heat 
for a prolonged period.  Newly developing high intensity focused ultrasound 
(HIFU) applications for mild HT generates heat with focused beams at a 
small volume, and scans through a defined region at high speed to elevate its 
local temperature. At a HIFU focused volume, the heat is on, after which the 
heat of that volume will be off until the next round of scanning arrives. The 
interval between two heat-on moments in HIFU is short for small tumors, and 
therefore is considered to provide continuous mild HT, but the interval will 
be longer when treating larger tumors in a multi focal approach. In this thesis, 
an external resistive electric heating coil is adopted to provide homogeneous 
mild HT at dorsal skin flap window chamber tissues. This applicator needs 
~10 minutes to reach tissue temperature of 41-42°C, therefore heat cycling is 
scheduled to remain at 42°C for 1 or 5 minutes to balance the ratio of on-off 
moments, (Chapter 6). On-off heat alternations cause transient blood flow, 
interstitial fluid flow and pressure changes, in turn augment intratumoral 
liposomal drug delivery. Besides the fact that on-off heat alternations trigger 
content release from TSL during heat-on moments. 
When mild HT is applied at a highly perfused tumor or regions of a tumor, local 
excessive heat is constantly removed from perfused regions through circulation 
also causing heat cycling effects. The study on heat cycling demonstrates that 
heat on and off stresses tumor vasculature to become permeable for liposome 
extravasation and interstitial penetration, and triggers content release from 
TSL. The concept of heat cycling brings an alternative to advanced liposomal 
drug delivery to solid tumors. 
Conclusion 
The overall goal of the thesis is to present the use of TSL and mild HT for 
advanced liposomal chemotherapy to solid tumors. TSL formulation is 
optimized regarding DSPE-PEG2000 concentration. Dox encapsulation is 
7112
Discussion
customized for the specified TSL formulations. Tumor vasculature response to 
thermal stress is evaluated among multiple tumor models. Thermal doses of 
mild HT to induce permeable tumor vasculature and to trigger content release 
from the TSL are determined. Mild HT is applied in different formats for 
optimal intravascular or interstitial drug release. A single conventional mild 
HT, two-step mild HT and heat cycling can tailor treatment planning, according 
to tumor type, size, location and perfusion. An optimal treatment planning of 
mild HT and systemic liposomal chemotherapy can be assigned to a multitude 
of solid tumors. Additionally, nanocarriers from many other categories besides 
TSL can benefit from intratumoral accumulation and subsequent interstitial 
release. Taking the advantage of tumor microenvironment manipulation by 
mild HT, nanocarriers can be further optimized for various purposes. Future 
studies involve imaging-guided drug delivery and release, specific targeting 
on elevated protein expression, cellular membrane binding and internalization, 
synergy of two and more nanocarrier populations. The effect of mild HT on 
tumor microenvironment needs to be vastly explored. The combination and 
optimization of the use of nanocarriers and mild HT will meet the needs to 
improve clinical anticancer treatment outcome. 
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Summary 
Liposomes are nano-sized drug carriers widely used to deliver 
chemotherapeutic compounds in cancer treatments. While prolonging drug 
retention in circulation and preventing certain toxic side-effects, liposomal 
drugs still need to overcome matters on specific accumulation in the tumor 
and controlled drug release. The aim of this thesis is to introduce local 
mild hyperthermia (HT) and thermosensitive liposomes (TSL) to liposomal 
chemotherapy, to improve therapeutic outcome. 
Chapter 1 introduces in more detail the background of the study and gives 
an introduction to the several sections of the thesis and research topics. In 
Chapter 2, we describe a TSL formulation composed of classic temperature 
sensitive phospholipids, omitting the lyso-lecithin used in a clinically applied 
formulation for ultrafast release, but with an optimized poly(ethylene glycol) 
(PEG) surface concentration for stability at physiological temperature and fast 
release at mild HT (41-43°C). These optimized TSL ensure a prolonged content 
retention at physiological temperature when exposed to serum proteins, and 
also feature in vitro and in vivo rapid content release at mild HT. At present, two 
major drug delivery approaches using TSL and mild HT are being proposed. 
The first approach aims to use mild HT in a two-step approach to first 
manipulate tumor vasculature, promoting enhanced liposome extravasation, 
followed by a second mild HT to trigger drug release. 
Chapter 3 investigates the first step in this approach; the effect of mild HT on 
tumor vasculature permeability for liposome extravasation and intratumoral 
penetration. Multiple thermal doses are compared for levels of liposome density 
in the extravascular extracellular space (EES), penetration depth in murine 
and xenograft tumor models. Mild HT induced heterogeneous intratumoral 
liposome accumulation in all tumor models. Liposomes extravasated through 
tumor vasculature and penetrated deep into the interstitial space following 
the HT enhanced interstitial fluid flow. 
A second drug delivery approach is the intravascular drug release approach 
in which circulating TSL are triggered to rapidly release their contents upon 
their passage through tumor vasculature. This approach is demonstrated 
in Chapter 4, which focuses on in vitro and in vivo profiling of doxorubicin 
(Dox) encapsulated in optimized TSL. Dox-TSL in vitro stability and release 
kinetics in serum, and in vivo tumor growth control and survival after a single 
treatment of intravascular Dox release are compared to Dox encapsulated in 
lyso-lipid based TSL, which is currently in clinical trials. Optimized Dox-TSL 
further prolonged tumor growth control and improved survival than lyso-
lipid based TSL when applied in combination with mild HT. 
Chapter 5 proposes the novel two-step mild HT approach. The first-step local 
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mild HT is for inducing permeable tumor vasculature, after which liposomal 
drugs are systemically administered at physiological tumor temperature. 
Liposomal drugs are allowed to circulate for two hours, to gradually 
accumulate in the EES in tumors through permeable tumor vasculature. Then, 
the second-step local mild HT is applied to trigger interstitial Dox release 
from extravasated Dox-TSL. Tumor growth control and survival after the 
two-step mild HT approach is compared to intravascular release approach. 
The two-step mild HT approach was less effective compared to intravascular 
release approach. However, the two-step mild HT approach is an alternative 
to conventional mild HT, and may be more beneficial to large and deep seated 
tumors when regional mild HT is required. 
Chapter 6 studies the effect of heat cycling on tumor vasculature permeability 
and content release kinetics of TSL. Heat cycling was used to mimic the 
clinical application of high intensity focused ultrasound (HIFU) based heating 
of large tumors. While HIFU, with a treatment focus of a few millimeters, 
is scanning through tumors, every fraction of a tumor is experiencing tissue 
heating and cooling alternately, resulting in a rather heterogeneous heat 
delivery. Through each heat cycle, contents are released from TSL and tumor 
vasculature accumulates heat stress affecting its permeability. The therapeutic 
efficacy of heat cycling is investigated and compared to continuous mild HT. 
Heat cycling induced hyperpermeable tumor vasculature for intratumoral 
liposomal drug accumulation, triggered intravascular Dox release from TSL, 
and effectively suppressed tumor growth, which was merely as sufficient as 
continuous mild HT. 
Chapter 7 discusses the results of the studies in relation to the current status 
of mild HT mediated drug delivery using TSL and presents an outlook for 
future developments and possible further improvements of this triggered 
drug delivery approach. 
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Samenvatting 
Liposomen zijn kleine vetbollen met een diameter van circa 100 nm en worden 
veel gebruikt als drager systeem voor chemotherapeutica in de behandeling 
van kanker. Hoewel insluiting van chemotherapeutica in liposomen de 
verblijftijd in de bloedbaan kan verlengen en bepaalde toxische bijwerkingen 
kan voorkomen, moeten de liposomen nog wel in hogere mate ophopen 
in tumoren en daar ook gecontroleerd hun inhoud vrijgeven. Het doel van 
het onderzoek beschreven in dit proefschrift is het gebruik van locale milde 
hyperthermie en thermosensitieve liposomen (TSL) om de therapeutische 
uitkomst van liposomale chemotherapie verder te verbeteren. 
In hoofdstuk 1 wordt de achtergrond van de studie nader geïntroduceerd 
en wordt een introductie gegeven op de verschillende onderdelen en 
onderzoeksonderwerpen van de studie. In hoofdstuk 2, beschrijven we 
een TSL formulering bereid met veelgebruikte temperatuur-gevoelige 
fosfolipiden, waarin lyso-lecithine, die in een klinische toegepaste formulering 
wordt gebruikt voor ultrasnelle release, niet is opgenomen. Wel is van deze 
TSL de concentratie poly(ethyleen glycol) (PEG) op het liposoom oppervlak 
geoptimaliseerd om TSL stabiliteit bij fysiologische temperatuur te combineren 
met een snelle afgifte van de inhoud tijdens milde hyperthermie (41-43 °C). 
Deze geoptimaliseerde TSL waren in staat langdurig hun inhoud vast te 
houden bij fysiologische temperaturen in aanwezigheid van serumeiwitten en 
gaven snelle afgifte van hun inhoud tijdens milde hyperthermie. Er worden 
twee belangrijke methoden voorgesteld om geneesmiddelafgifte te verkrijgen 
met TSL in combinatie met milde hyperthermie. De eerste methode heeft als 
doel milde hyperthermie toe te passen in een twee-staps aanpak waarin de 
eerste hyperthermiebehandeling het tumorvaatbed manipuleert en daarmee 
accumulatie van liposomen in de tumor promoot, gevolgd door een tweede 
milde hyperthermiebehandeling die chemotherapie afgifte induceert. 
Hoofdstuk 3 bestudeert de eerste stap van deze methode; het effect 
van milde hyperthermie op de permeabiliteit van tumorbloedvaten, op 
liposoomuittreding en verdere doordringing in het tumorweefsel. De 
effecten van verschillende temperatuurdoses op liposoomophoping en 
doordringingsdiepte in de tumor zijn vergeleken in verschillende muizen 
en humane (xenograft) tumor modellen. Milde hyperthermie induceerde 
heterogene intratumorale ophoping van liposomen in alle tumormodellen. 
Liposomen extravaseerden uit tumorbloedvaten en drongen ver het tumor 
interstitium binnen onder invloed van de door de hyperthermie toegenomen 
interstitiële vloeistofstroom. 
De tweede methode voor geneesmiddelafgifte door middel van TSL en 
hyperthermie is de intravasculaire afgifte, waarbij circulerende TSL tijdens 
passage door tumorbloedvaten worden verwarmd en vervolgens snel locaal 
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in het tumorgebied hun inhoud afgeven. Deze methode is gedemonstreerd in 
hoofdstuk 4, wat zich richt op de in vitro en in vivo stabiliteit en afgiftekinetiek 
van doxorubicine (Dox) ingesloten in geoptimaliseerde TSL. Van deze Dox-
TSL is in vitro de stabiliteit en afgiftekinetiek bepaald in serum en zijn in vivo 
de effecten op tumorgroei en overleving van tumordragende muizen na 
eenmalige behandeling vergeleken met een behandeling met Dox in lysolipide-
gebaseerde TSL, een formulering die op dit moment in klinische studies wordt 
gebruikt. De geoptimaliseerde Dox-TSL waren in staat tumorgroei sterker te 
remmen en de overlevingsduur van tumordragende muizen te verlengen in 
vergelijking met de lysolipid-Dox-TSL behandeling, in combinatie met milde 
hyperthermie. 
In hoofdstuk 5 wordt de twee-staps milde hyperthermie behandelingsmethode 
nader onderzocht. De eerste locale milde hyperthermie zal het tumorvasculatuur 
meer permeabel maken, waarna de liposomale chemotherapie systemisch 
wordt toegediend bij een fysiologische tumor temperatuur. Liposomen krijgen 
2 uur de tijd voor circulatie en zullen in die periode geleidelijk ophopen in de 
tumor door de permeabele tumorbloedvaten. Vervolgens zal de tweede milde 
hyperthermie behandeling worden toegepast om in het tumor interstitium 
Dox afgifte te stimuleren van geëxtravaseerde liposomen. De effectiviteit van 
deze twee-staps milde hyperthermie methode op tumor groei en overleving 
van tumordragende muizen is vergeleken met die van de intravasculaire 
afgifte en bleek minder groot. Desalniettemin biedt de twee-staps methode 
een belangrijk alternatief die voordeel kan opleveren bij de behandeling van 
grote en diep gelegen tumoren die normaliter door middel van regionale 
milde hyperthermie worden behandeld. 
Hoofdstuk 6 bestudeerd de effecten van warmtecycli op de permeabiliteit 
van tumorbloedvaten en afgifte van de inhoud van TSL. De toepassing van 
warmtecycli benadert de klinische toepassing van high intensity focused 
ultrasound (HIFU) voor de verwarming van grote tumoren. Wanneer tijdens 
een dergelijke HIFU behandeling de tumor wordt gescand met gericht 
hoog intens ultrageluid met een behandelingsfocus van slechts enkele 
millimeters, zullen de verschillende delen van de tumor afwisselende cycli 
van opwarming en afkoeling ondervinden, hetgeen leidt tot een heterogene 
temperatuursverdeling. Tijdens iedere warmteclycus zal inhoud van de 
TSL in dat gebied worden vrijgegeven en ondervindt het tumorvasculatuur 
warmte stress, hetgeen de vaatpermeabiliteit zal verhogen. De therapeutische 
werking van warmtecycli is onderzocht en vergeleken met de toepassing 
van continue milde hyperthermie. Toepassing van warmtecycli induceerde 
naast verhoogde tumorvaatpermeabiliteit en extravasatie van liposomen ook 
intravasculaire Dox afgifte uit TSL en was in staat om de tumorgroei effectief 
te onderdrukken in een vergelijkbare mate als bij de combinatie van continue 
milde hyperthermie en Dox-TSL. 
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In hoofdstuk 7 worden de resultaten van de studies bediscussieerd in verhouding 
tot de huidige status van milde hyperthermie-gemedieerde chemotherapie 
afgifte door TSL. Tevens presenteert dit hoofdstuk een vooruitzicht op 
toekomstige ontwikkelingen en mogelijke verdere verbeteringen van deze 
warmtegecontroleerde chemotherapie afgifte methode. 
by Gerben A. Koning 
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Medical Intern at Guangzhou Military General Hospital of China, Guangzhou, 
China. 
Major clinical skills: 
Clinical diagnoses, radiological diagnoses, surgery, clinical treatment 
therapies, oriental-style therapies, etc.. 
Laboratory skills: 
Dorsal skin flap window chamber and mammary window models, liposomes, 
cell culture, chemosensitivity assay, fluorescent spectrometry, intravital 
confocal microscopy, DNA thermal melting assay, etc.. 
Certificates: 
Legal qualification as an animal experimentalist (Article 9). 
Languages: 
Chinese mandarin, native.  
English, proficient.  
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Awards: 
1. Nominatee for Chinese Government Award for Outstanding Self-Financed 
Students Abroad 2012. 
2. New Investigator Award Winner at STM (Society for Thermal Medicine) 
in Portland, OR, in 2012.  
3. Nominatee for Chinese Government Award for Outstanding Self-Financed 
Students Abroad 2011. 
4. Student Award Winner for Biology at ESHO (European Society for 
Hyperthermic Oncology) in Aarhus, Denmark, in 2011. 
Grants: 
KWF (Dutch Cancer Society) travel grants 2011.  1. 
Visiting researcher: 
08/04/2011 – 26/04/2011, Prof. Mark Dewhirst’s lab at Duke university, 1. 
Durham, North Carolina, USA. 
27/06/2009 – 04/07/2009, Prof. Rolf Issels’ lab at University Hospital 2. 
Grosshadern, Ludwig-Maxililians University, Munich, Germany. 
Lectures: 
STM2012 in Portland, OR, USA, “Launching the chemo bombs for 1. 
advanced drug delivery to solid tumors”. 
Molmed Day 2012, Rotterdam, NL, “Launching the chemo bombs for 2. 
advanced drug delivery to solid tumors”. 
ESHO 2011 in Aarhus, Denmark, “Mild hyperthermia induced liposomal 3. 
drug delivery and triggered drug release in solid tumors”. 
KWF-Hyperthermia on 11/11/2011 in Amsterdam, NL, “Launching the 4. 
chemo bombs for advanced drug delivery”. 
STM 2011 in New Orleans, LA, USA, “Hyperthermia induced intratumoral 5. 
liposomal drug delivery and triggered release”. 
Duke University in Durham, NC, USA, 19/04/2010. “Mild hyperthermia 6. 
induced liposomal drug delivery and triggered drug release in solid 
tumors”. 
MUSC (Medical University of South Carolina) in Charleston, SC, USA, 7. 
11/04/2011, “Mild hyperthermia and thermosensitive liposomes to 
improve chemotherapy delivery to solid tumors”. 
Targeted Nanomedicine 2010 in Leiden, NL, “Hyperthermia induced 8. 
intratumoral liposomal drug delivery and triggered release”. 
KWF-Hyperthermia 2010 in Rotterdam, NL, “Two-step hyperthermia 9. 
guided liposomal anticancer drug delivery”. 
ESHO 2010 in Rotterdam, NL, “A two-step approach for intratumoral drug 10. 
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delivery using optimized long-circulating thermosensitive liposomes and 
mild hyperthermia”. 
STM 2010 in Clearwater Beach, FL, USA, “A two-step approach 11. 
for intratumoral drug delivery using optimized long-circulating 
thermosensitive liposomes and mild hyperthermia”. 
Imagination 2009 in Nijmegen, NL, “Triggered content release from 12. 
optimized stealth thermosensitive liposomes using mild hyperthermia”. 
STM 2009 in Tucson, AZ, USA, “Triggered content release from optimized 13. 
stealth thermosensitive liposomes using mild hyperthermia” 
Chair: 
Co-chair in Nanotechnology and Thermal Medicine session at STM 2012. 1. 
Co-chair in Thermosensitive nanomedicine session at ESHO 2010. 2. 
Memberships: 
Student member of STM in 2009-2012. 
Student member of ESHO in 2010-2012. 
Associate member of AACR 2010-2013. 
Junior Scholar in Training member of RRS in 2012. 
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Dr. Martin Hossann from University Hospital of Munich, Germany, who 
contributed to my study on so many levels. Some people were with me on an 
earlier journey at University of Bradford, UK. Dr. Steve M. Picksley was the 
light that guided me through the MSc tunnel and the North Star that oriented 
my PhD direction. Dr. Roger M. Phillips’ passion in science showed me what 
research was truly about. Dr. Richard T. Wheelhouse mentored me that 
preciseness and responsibility were the foundation that any study should be 
built on. It is my fortune to have met these wonderful scientists, supporting 
me excel in cancer research. 
It was my pleasure to work with colleagues at Erasmus MC and international 
collaborators, in particular, Mark Halberstadt, whose dedication to my study 
meant a great deal to me. Dr. Gert van Cappellen brightened my vision in 
imaging. Dr. Dieter Haemmerich, Dr. Lars H. Lindner and Prof. Gerard C. 
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work with knowledgable Michiel Bolkestein. To Ann L.B. Seynhaeve and 
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(STM) and European Society for Hyperthermic Oncology (ESHO), where 
I got to meet legendary scientists and experts. It would be my only wish to 
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Cressman and so many other talented researchers. 
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me a terrific project. It is  everything I hoped all my study over the years could 
ever lead to. Thank you for making my dream come true.   
I shall thank my parents for believing in me and supporting me, my 
grandparents who taught me seemingly simplest things in life, which had 
however been life-changing. I mustn’t forget my dearest Mietsie and Pepper, 
who bring tons of joy into my life. 
“If I have seen further it is by standing on the shoulders of giants”, said Isaac 
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Li Li was born early in the morning on Sunday 26th July 1981, probably the only 
time she ever gets up before sunrise, not to mention it was a Sunday. When 
she was ten, her grandfather was diagnosed with a thrombus in the brain stem 
and died in four days. After learning the fact that there was no doctor who 
would operate on him because of the disease location, she decided to become 
a surgeon herself to master the skills a surgeon should have. In 2000, she was 
selected as one of the only two females from Liaoning province, which ranks 
14th in P.R. China with 43,746,323 inhabitants (2010), to study medicine at the 
First Military Medical University of P.R. China, in Guangzhou, Guangdong 
province. 
When she was twenty, her grandmother, who had never smoked a single 
cigarette, was diagnosed with lung cancer and died in one hundred days. She 
realized how finite a clinician could offer to a cancer patient and how desperate 
it was to find a cure. Therefore, in 2005, she chose MSc in Biomedical Sciences 
at University of Bradford, UK and focused on cancer. From 2008 to 2013, she 
spent 5 years as a PhD student at Erasmus MC, Rotterdam, in the Netherlands 
to research on heat and nanomedicine related strategies for chemotherapy. 
Since May 2013, she works in Prof. Dewhirst’s lab at Duke University, Durham, 
NC, USA and dedicates herself to fight in the war against lung cancer. 
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Afterword
A thesis with an afterword is rare and to my knowledge unprecedented. 
When Li asked me to write an afterword I was surprised and honored, but 
not completely sure of what was expected from me. Why an afterword in a 
Thesis? Mostly a thesis is an overview of the candidates work, it described 
the why and how, shows achievements and chapters contain often published 
work. What would an afterword add? 
Typically a Dutch thesis defense comes with a number of printed and 
colorfully covered little books, which do not only give the candidate an 
additional headache but also rips her of her last money. And for what? Mostly 
these theses disappear in drawers or are used to level computer screens, and 
if lucky they and up on a shelf. But reading a thesis; that is something else. 
In most cases the recipient of the unrecognized treasure flipped through it 
to check what had been published: how well did this one do. Or when more 
involved, went through the effort to read the acknowledgement, hoping to 
see his or her name or find out who is being thanked and why. Also the CV is 
popular: how did she get here, what did she do and most of all where is she 
going? Is it worth the effort I wonder? 
But, looking back at the work presented here I recognize the duty I have here. 
Isn’t a thesis, this thesis, a beautiful compilation of scientific work, yes showing 
indeed the persons work, but more so a line, a development, bringing the field 
forward. And when the proud owner of this thesis does makes the effort, and 
sit down, and read this thesis from start, through the progression made, till 
the goal which has been reached, scientific and personal growth will become 
apparent. 
That is, I guess, my duty. To make you, proud owner of this thesis, read it. 
Sit down, go back to chapter 1, ignore for now the acknowledgement, or the 
so popular CV, and start reading. Because this work is a result of melting 
together numerous disciplines, builds on insight coming from all directions 
and shows how powerful and successful working together can be. Starting 
long time ago with isolated perfusions, liposomal formulations, triggered 
drug release, tumor manipulation, and recently hyperthermia a research line 
converged which is not only worth the reading but also worth the attention. 
I am proud to deliver this afterword as I am proud of Li, of the work she 
conducted, of the results obtained and proud when realizing that where 
we came from developed so nicely. And I hope that you, the reader of this 
Afterword, will share my feelings.
by Timo L.M. ten Hagen


